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Abstract 
 
 
α-synuclein is a neuronal protein involved in several neurodegenerative disorders, 
including Parkinson’s Disease (PD). Misfolding and accumulation of α-synuclein into 
cytoplasmic inclusions correlate with the pathogenesis of PD and are reproducible upon 
overexpression in yeast. GAL1 promoter-driven wild type (WT) and mutant α-synucleins 
were studied in parallel with their fluorescently tagged counterparts. Overexpression of 
WT and of A53T mutant α-synuclein impaired yeast growth and resulted in cytoplasmic 
accumulations. Fluorescently-tagged versions preserved these effects when the tag was 
fused C-terminally via a linker. Three WT copies or two A53T copies integrated into one 
genomic locus resulted in significant growth impairment and accumulation in yeast and 
represent thresholds for toxicity. A30P mutant α-synuclein had only a mild inhibitory effect 
to yeast growth and formed aggregates transiently when overexpressed. The triple proline 
designer mutant A30P/A56P/A76P did not affect growth or formed inclusions. Promoter 
shut-off experiments revealed that yeast cells can recover from transient α-synuclein 
expression by clearing aggregates. Proteasomal inhibition by the drug MG132 or by a 
cim3-1 genetic mutation did not significantly impair aggregate clearance. This suggests 
only a minor contribution of the 26S proteasome to α-synuclein degradation. In contrast, a 
major impairment in clearance in yeast cells treated with vacuolar protease inhibitor 
phenylmethylsulfonyl fluoride suggested a prominent function of vacuolar proteases. 
Consistently, a pep4 yeast mutant characterized by vacuolar defects presented impaired 
clearance ability. A atg1 yeast mutant deficient in autophagy showed a delay in the 
aggregate clearance response, suggestive of autophagy involvement in the process. α-
synuclein aggregates were also cleared when cells were treated with the autophagy-
inducing drug rapamycin. Aggregate formation was impaired when cells were pre-treated 
with the drug, validating the involvement of autophagy in α-synuclein pathobiology. In turn 
α-synuclein was able to influence autophagy. While A30P α-synuclein transiently up-
regulated autophagy, A53T had an inhibitory effect. WT and A53T α-synucleins 
additionally delayed the induction of autophagy. A cim3-1atg1 double mutant cleared α-
synuclein aggregates after promoter shut-off, suggesting that additional cellular 
mechanisms contribute to clearance. These data provide insight into the pathways yeast 
cells use for clearing -synuclein and offer novel perspectives for therapeutic intervention. 
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Zusammenfassung 
 
α-Synuclein ist ein neuronal exprimiertes Protein, das an neurodegenerativen Krankheiten 
wie Morbus Parkinson beteiligt ist. Fehlenhafte Faltung und Akkumulation in 
zytoplasmatische Einschlusskörper charakterisieren die Pathogenese dieser Krankheit. 
Diese sind auch durch Überexpression von α-synuclein in Hefezellen nachvollziehbar. In 
dieser Arbeit wurden das GAL1-Promotor gesteuerte Wildtyp (WT) α-Synuclein mit 
mehreren Varianten mit und ohne Fluoreszenzmarkierung im Modellsystem 
Saccharomyces cerevisiae untersucht. Die Überexpression des WT- und A53T-mutierten 
α-synucleins hemmte das Hefewachstum und resultierte in zytoplasmatischen 
Aggregaten. C-terminal fluoreszenzmarkierte Varianten zeigten die gleichen Effekte. Die 
Integration von drei WT- oder zwei A53T-Kopien in einen einzigen genomischen Lokus 
resultierten in einer signifikanten Wachstumshemmung sowie Akkumulation und wurden 
somit als Toxizitätsschwelle definiert. Die A30P Variante hatte nur einen gering 
hemmenden Effekt auf das Hefewachstum und bildete nur transiente Aggregate bei 
Überexpression. Im Gegensatz dazu zeigte die triple-Prolin-Variante A30P/A56P/A76P 
weder eine Wachstumshemmung noch nachweisbare Aggregate. 
Promoterabschaltungsexperimente zeigten, dass Hefezellen Aggregate auflösen können. 
Das 26S Proteasom spielt bei diesem α-Synuclein Abbau keine wichtige Rolle, da eine 
Proteasomhemmung durch das Medikament MG132 oder durch eine genetische cim3-1 
die Auflösung der Aggregate wenig beeinflußt. Im Gegensatz dazu fuhrt die Hemmung 
durch den vakuolaren Proteaseninhibitor Phenylmethylsulfonylfluorid zu einer deutlichen 
Inhibition bei der Auflösung von α-Synuclein Aggregaten. Ebenso zeigte die pep4 
Hefemutante eine verminderte Fähigkeit der Aggregatklärung. Die Autophagie-defiziente 
Hefemutante atg1 zeigte eine verzögerte Klärung, was auf eine Beteiligung von 
Autophagie an dem Prozess schließen lässt. Dies wurde dadurch bestätigt, dass α-
synuclein-Aggregate auch reduziert wurden, wenn die Zellen mit dem Autophagie-
induzierenden Medikament Rapamycin behandelt wurden. Rapamycin vorbehandelte  
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Zellen zeigten zusätzlich eine verminderte Aggregatbildung, was die Bedeutung von 
Autophagie in der α-synuclein Pathobiologie weiter validiert. Im Gegenzug hatte α-
Synuclein auch einen Einfluss auf Autophagie. Während A30P α-Synuclein Autophagie 
transient hoch-regulieren konnte, hatte A53T einen hemmenden Effekt. WT und A53T α-
synuclein zusätzlich verzögerten die Induktion von Autophagie. Eine cim3-1atg1 
Doppelmutante klärte Aggregate nach Promotorabschaltung, was andeutet dass 
zusätzliche zellulare Mechanismen zur Klärung beitragen müssen. Diese Daten bieten 
neue Einsichten in die Prozesse, die Hefezellen benutzen um α-synuclein Aggregate zu 
entfernen und eröffnen neue Perspektiven für therapeutische Eingriffe.  
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1. INTRODUCTION  
 
1.1 Parkinson’s Disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disease, 
belonging to the group of motor system disorders (Lang and Lozano, 1998). The disease 
progresses as the dopaminergic neurons of the ventral midbrain region called substantia 
nigra pars compacta begin to die (Fearnley and Lees, 1991; Meissner et al., 2011). 
Neuronal cell death affects the central nervous system and leads to a series of symptoms, 
such as postural instability, tremor, akinesia (muscle rigidity), bradykinesia (slowness of 
movement) and overall poor balance and coordination (Galvin et al., 2001; Meissner et al., 
2011). Very often, these symptoms are accompanied by psychological syndromes like 
depression and emotional instability (Giupponi et al., 2008). This is due to the depletion of 
dopamine, which leads to an imbalance of other neurotransmitters such as acetylcholine, 
glutamate or GABA (Wichmann and DeLong, 2003). Typically, sporadic PD symptoms are 
more subtle at the onset of the disease, before the age of 60, and worsen progressively 
(Lang and Lozano, 1998).    
While the causes of PD are still unclear, several factors, including environmental (e.g. 
trauma, drugs, toxins), epigenetic and genetic, have been proposed to contribute to the 
disease. Toxins suspected to promote PD are pesticides and heavy metals, such as 
manganese, copper and iron, which are able to generate reactive oxygen species 
characteristic of PD (Chiueh et al., 2000; Jenner, 1998). Genetic causes of PD can be 
divided in two categories: sporadic/idiopathic (95% of the cases) and familial (5% of the 
cases). Mutations in genes like SNCA, PRKN, PINK1, DJ-1, MAPT, UCH-L1, ATP13A2, 
 
“It is the theory that decides what we can observe.” 
 
  Albert Einstein 
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LRRK2 and HtrA2/Omi involved in oxidative stress, mitochontrial disfunction and protein 
quality control are often associated with the disease (Biskup et al., 2008; Kawamoto et al., 
2008). 
Since there is currently no cure for PD, common therapies aim at delaying or ameliorating 
the symptoms while research focuses on understanding toxicity mechanisms and 
providing protective solutions. Due to the ageing of the world population, the importance 
of Parkinson's disease as a public health issue has tremendously increased over the past 
decades. 
 
1.2. α-synuclein in Parkinson’s disease  
The molecular basis of PD is the accumulation of intracellular proteinaceous inclusions 
known as Lewy bodies (LBs) (Figure 1), which contain proteins like α-synuclein, ubiquitin, 
synphilin-1 and several cytoskeletal proteins (Forno et al., 1996). The major constituent of 
LBs is the aggregated protein α-synuclein (Spillantini et al., 1997). 
 
 
Figure 1. Morphology of Lewy bodies in Parkinson patients. Nerve cell with three Lewy bodies 
double-stained for α-synuclein and ubiquitin. The halo of each Lewy body is strongly 
immunoreactive for ubiquitin, whereas both the core and the halo of each Lewy body are 
immunoreactive for α-synuclein. Scale bar = 10 µm. (Spillantini et al., 1998a).  
 
α-synuclein inclusions have also been reported in other neurodegenerative diseases 
besides PD, such as Multiple System Atrophy, neurodegeneration with brain iron 
accumulation type-1, dementia with Lewy Bodies and Alzheimer’s disease, collectively 
referred to as α-synucleinopathies (Duda et al., 2000; Spillantini et al., 1998a; Spillantini et 
al., 1997; Tofaris and Spillantini, 2007). 
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α-synuclein is a small neuronal protein encoded by the SNCA gene in the PARK1 gene 
locus (Cookson, 2005). The protein belongs to the synuclein family along with β and γ 
isoforms encoded by the SNCB and SNCG alleles respectively (Maroteaux and Scheller, 
1991). Concerning molecular features, α-synuclein is a 140 amino acid protein with a 
molecular weight of 17 kDa. It contains a series of N-terminal imperfect repeats based on 
the amino acid motif KTKEGV which occurs seven times starting from the N-terminus until 
the core region of the protein (Figure 2).  The central region of α-synuclein is strongly 
hydrophobic and promotes dimerization (Giasson and Lee, 2001, Tong et al., 2010). 
 
 
 
Figure 2. α-synuclein and secondary structure propensity. The N-terminus of α-synuclein (red) 
adopts an α-helical structure upon binding to lipid membranes. Seven 11-mer repeats of the motif 
KTKEGV spread from the N-terminus towards the core of the protein (gray). The non-amyloid 
component or NAC (blue) is hydrophobic and prone to forming β-sheet aggregates. The C-terminus 
(green) is largely negatively charged and promotes protein solubility. Amino acid positions 30, 
where an alanine is exchanged to a proline, 53, where an alanine is exchanged to a threonine and 
47, where a glutamic acid residue is exchanged to a lysine are PD-related mutations associated 
with early onset of the disease. Adapted from Vamvaca et al., 2009. 
 
The N-terminal region of α-synuclein is essential for oligomerization (Karube et al., 2008), 
whereas the highly acidic C-terminal region is involved in protein-protein interactions 
(Cookson, 2005) and may inhibit aggregation (Murray et al., 2003). Interestingly, 
alterations in the C-terminus accelerate aggregation (Mishizen-Eberz et al., 2005; 
Vamvaca et al., 2009).  α-synuclein misses a stable tertiary structure in solution. Hence, 
starting from its monomeric structure, the protein can form coiled-coils, β sheets and 
A30P 
A53T 
E47K 
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complex multimeric structures like fibrils, fibers and aggregates (Giasson et al., 1999) 
(Figure 2).   
Several observations have been made with respect to the function of α-synuclein. The 
protein was primarily found in neural tissue at presynaptic terminals where it may serve as 
molecular chaperone in vesicular fusion (Bonini and Giasson, 2005; Chandra et al., 2005). 
α-synuclein has been shown to function in maintaining neurotransmitter vesicular pools 
(Jensen et al., 1998), synaptic plasticity (Abeliovich et al., 2000; Clayton and George, 
1998) and phospholipid metabolism (Golovko et al., 2009; Sharon et al., 2001). 
Furthermore, it was reported to interact with tubulin (Alim et al., 2002) and to act as a 
microtubule-associated protein, similarly to tau protein involved in Alzheimer’s disease 
(Alim et al., 2004).  
The involvement of α-synuclein in PD is sustained by the fact that allele multiplication of 
the wild type SNCA locus such as duplication or triplication was linked to a familial form of 
the disease (Hardy et al., 2006; Singleton et al., 2003). Additionally, three missense 
mutations, A30P, A53T and E46K, correlated with autosomal dominant early-onset PD 
(Krüger et al., 1998; Polymeropoulos et al., 1997). These mutations rendered α-synuclein 
more prone to forming amyloid fibrils (Cookson et al., 2005; Greenbaum et al., 2005). To 
understand the relationship between α-synuclein’s structural features and its toxicity, 
research has further focused on artificially designing new α-synuclein mutants (Karpinar et 
al., 2009). For example, A30P/A56P/A76P or triple proline (TP) α-synuclein is a structure-
based designer mutant which besides the A30P mutation bears two additional Alanine to 
Proline substitutions in the β sheet-forming region of α-synuclein. These changes interfere 
drastically with aggregation. However, despite reducing α-synuclein’s fibril formation rate, 
they do not prevent the protein from being toxic (Karpinar et al., 2009).    
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1.2.1. α-synuclein aggregation and toxicity   
The aggregation pathway of α-synuclein begins with the formation of soluble unstable 
oligomeric species and is promoted by an initial binding of the protein to the plasma 
membrane. Due to its hydrophobic core defined by amino acids 71-82 (Chandra et al., 
2003), α-synuclein has a high affinity for binding to lipid membranes. Upon binding, the 
protein changes conformation and forms two helical domains connected by a small non-
helical linker. The interaction of the hydrophobic residues between the α-helices leads to 
β-sheet formation and oligomerization (Zhu and Fink, 2003). Later on, α-synuclein self-
assembles into protofibrils which mature into fibrils and amyloids (Figure 3). These 
accumulate in inclusion bodies (Auluck et al., 2010), often denominated aggregates. 
Interestingly, it is assumed that the fibrilar forms not the aggregates are toxic α-synuclein 
species in PD (Goldberg and Lansbury, 2000; Karpinar et al., 2009). Aggregates might 
thus have a cytoprotective role, isolating toxic α-synuclein species (Tanaka et al., 2004). 
 
 
Figure 3. α-synuclein requires lipid interactions to form dimers, oligomers and mature 
fibrils. In the presence of a lipid membrane, the N terminus of α-synuclein forms two α-helices 
which allow the protein to associate with the surface of the membrane. An increase in α-synuclein 
concentration stabilizes membrane interactions and facilitates the formation of α-synuclein dimers 
on the membrane surface. Through dimerization, α-synuclein adopts a β-sheet secondary structure 
which, by association with α-synuclein monomers or other dimers, leads to oligomer formation. 
Oligomers promote the development of fibrils which deposit as amyloids within Lewy bodies. 
(Auluck et al., 2010). 
Dimerization 
with β-sheet 
formation 
Oligomerization 
Dimerization with β-sheet formation 
Oligomerization 
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It has been proposed that α-synuclein may first be nitrated (Giasson et al., 2000; Paxinou 
et al., 2001), phosphorylated (Ellis et al., 2001; Fujiwara et al., 2002; Recchia et al., 2004), 
glycosylated (Shimura et al., 2001) or truncated (Liu et al., 2005), rather than engage in 
aggregation as the full-length unmodified protein. Moreover, LBs containing α-synuclein 
are ubiquitinated (Cookson et al., 2005).  
Accumulation of misfolded α-synuclein elicits toxic effects on common cellular processes. 
Consequences include mitochondrial dysfunction, accumulation of reactive oxygen 
species, impaired protein clearance, defective ER-Golgi trafficking and inhibition of 
histone acetylation (Cole et al., 2002; Cooper et al., 2006; Greenamyre et al., 2003; 
Kontopoulos et al., 2006; Martin et al., 2006; Tanaka et al., 2001).  
 
1.2.2 Yeast as model for Parkinson’s disease 
While humans, mice and rats have well-conserved α-synuclein, no homologues have 
been reported in lower organisms like E. coli, S. cerevisiae, C. elegans or D. 
melanogaster (Lavedan et al., 1998). Nevertheless, mice, rats, flies, worms and yeasts 
altogether have been implemented as model systems to understand the molecular basis 
of PD (Chen and Feany, 2005; Giasson et al., 2002; Kahle et al., 2000; Lakso et al., 2003; 
Maroteaux and Scheller, 1991; Matsuoka et al., 2001; Outeiro and Lindquist, 2003; van 
der Putten et al., 2000). 
In particular, the budding yeast Saccharomyces cereisiae is a powerful model system due 
to extensive genetic tools available and rapid growth. Belonging to the group of fungi, S. 
cerevisiae is a single-cell organism with the typical cellular compartmentalization of an 
eukaryote. The haploid genome of yeast contains 16 chromosomes with more than 6000 
open reading frames (Goffeau et al., 1996) and yeast genes bear 60% homology to 
human genes (Mager and Winderickx, 2005). Due to the fact that basic molecular 
pathways involved in cellular homeostasis are highly conserved from yeast to human, S. 
cerevisiae is a very convenient model to study human diseases. 
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Although yeast does not endogenously produce α-synuclein or homologues (Lavedan et 
al., 1998), heterologous expression of the protein results in cytoplasmic inclusions and 
yeast growth impairment (Outeiro and Lindquist, 2003), reminiscent of PD pathogenesis. 
Many other aspects of α-synuclein pathobiology present in higher eukaryotes can be 
mimicked in yeast, for example, lipid droplet accumulation or defects in vesicle trafficking 
(Outeiro and Lindquist, 2003). 
 
1.3. Cellular degradation systems   
Protein homeostasis plays an important role in maintaining a balance between the 
synthesis of new proteins and the degradation of proteins which are damaged or which 
are no longer needed in a specific environment. Protein degradation is essential for 
normal cell growth and development in processes like cell cycle progression, transcription 
and cell signaling (DeMartino and Slaughter, 1999). Similarly to mammalian cells, two 
major cellular systems are responsible for protein degradation in yeast: the ubiquitin-
proteasome system (UPS) and autophagy/vacuolar pathways. The importance of these 
systems in cellular homeostasis has been demonstrated by inhibition with drugs like 
MG132, acting on the proteasome, and phenylmethanesulfonyl fluoride (PMSF), blocking 
vacuolar pathways (Lee and Goldberg, 1998) (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Protein degradation routes in yeast. Abnormal, short-lived and ER-associated proteins 
are targeted for proteasomal degradation while membrane-associated, long-lived and extracellular 
proteins are degraded by vacuolar pathways. Drugs used to inhibit these systems are MG132 and 
β-lactone for the proteasome and PMSF for vacuolar pathways. (Lee and Goldberg, 1998). 
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1.3.1 The Ubiquitin-Proteasome System (UPS) 
In eukaryotic cells, proteasomes are found in the cytoplasm, in perinuclear regions and 
inside the nuclei (Wojcik and DeMartino, 2003). The 26S proteasome is a multienzyme 
complex which degrades cellular polyubiquitinated proteins to short peptides in an ATP-
dependent manner. It consists of two major subcomplexes, the 19S regulatory particle 
and the 20S core particle involved in catalysis.  
The 19S complex determines substrate specificity and contains two subcomplexes, the 
base and the lid. The 19S base is composed of six distinct AAA+ family ATPases (Rpt1 to 
6) and three non-ATPase subunits (Rnp1, 2 and 10). The 19S lid complex is made up of 
eight non-ATPase subunits which can be released from the proteasome (Ciechanover, 
2006). Two such 19S particles are positioned at both ends of the 20S subunit, where the 
ATP-dependent interaction promotes opening of pores and provides an access channel 
for substrates entering the catalytic maw (Glickman and Ciechanover, 2002).  
The 20S complex is composed of two copies of fourteen different gene products (α1 to 7 
and β1 to 7) arranged in four axially stacked heptameric rings. The two central β rings 
which contain multiple proteolytic sites and are involved in degradation (Glickman and 
Ciechanover, 2002).  
Protein degradation by the UPS follows a well-defined pathway which begins with labeling 
of the protein to be degraded.  Labeling corresponds to the covalent attachment of the 
small protein ubiquitin which is first activated by the ubiquitin-activating enzyme E1 in an 
ATP-dependent reaction. An ubiquitin carrier protein, E2, undertakes the ubiquitin 
molecule and binds ubiquitin-protein ligase E3 which is already bound to the target 
protein. E3 finally transfers the ubiquitin molecule to a lysine side chain of the target 
protein. Once this ubiquitination round on the target protein is completed, additional 
rounds follow on the ubiquitin lysine residues, resulting in a polyubiquitin chain on the 
protein to be degraded. Apart from degradation purposes, polyubiquitin labelling at 
different lysine residues of ubiquitin regulates protein stability, activity and localization 
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(Glickman and Ciechanover, 2002; Haas and Siepmann, 1997). The ubiquitinated protein 
is recognized by the 19S regulatory particle of the proteasome, which unfolds it and 
passes it to the 20S core particle for degradation. The peptide products are hydrolyzed to 
amino acids and recycled (Figure 5) (Lee and Goldberg, 1998).  
 
 
Figure 5. Protein degradation via the ubiquitin-proteasome pathway. The target protein is first 
conjugated to ubiquitin in a reaction involving an ubiquitin-activating enzyme (E1), an ubiquitin-
carrier enzyme (E2) and an ubiquitin-protein ligase (E3). Upon several rounds of ubiquitination, the 
substrate is recognized by the 19S complex of the 26S proteasome and degraded in the 20S core 
to small peptides which are further hydrolysed into amino acids. (Lee and Goldberg, 1998). 
 
Control of cellular protein levels by the UPS is essential for many cellular functions, 
including cell proliferation, differentiation, stress response and apoptosis (Naujokat and 
Hoffmann, 2002).  UPS inhibition leads to an accumulation of undegraded proteins which 
can aggregate and lead to pathological conditions, such as neurodegeneration (Bedford et 
al., 2008; Betarbet et al., 2005; Olanow and McNaught, 2006).  
 
1.3.2 Autophagy and the vacuole  
The yeast vacuole is the correspondent of the mammalian cell lysosome. In yeast, this is 
the largest organelle, taking up 60% of the cell volume. Similarly to the UPS, the vacuole 
is also involved in protein degradation. Contrary to the UPS, which is responsible for the 
hydrolysis of short-lived proteins, the vacuole degrades long-lived proteins (Lee and 
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Goldberg, 1998). There are several pathways used by proteins to reach the vacuole: 
sorting of vacuolar proteins in the late Golgi, endocytosis of proteins from the cell surface, 
cytoplasm to vacuole targeting, autophagy and vacuolar inheritance from mother to 
daughter cells using homotypic fusion to fuse vacuolar vesicles (Bryant and Stevens, 
1998). 
Autophagy or “self-eating” is the highly conserved degradation of long-lived cytosolic 
proteins or organelles and it can be divided into three processes: microautophagy, 
macroautophagy and chaperone-mediated autophagy (CMA). Micro- and 
macroautophagy are present in yeast while CMA is not (Klionsky, 2005). Microautophagy 
defines the transfer of cytosolic components into the lysosome by direct invagination of 
the lysosomal membrane, followed by the budding of vesicles into the lysosomal lumen 
(Marzella et al., 1981). Macroautophagy is based on the formation of a double-membrane 
vesicle, the autophagosome, which sequesters cytosolic material and delivers it to the 
lysosome for degradation (Marzella et al., 1981). Chaperone-mediated autophagy is the 
only selective form of autophagy, where the substrates to be degraded are specifically 
recognized and transported inside the lysosome (Cuervo and Dice, 1998) (Figure 6). 
 
 
Figure 6. Types of autophagy. Microautophagy refers to the direct sequestration of cytosolic 
components through lysosomal membrane invaginations. In macroautophagy, cargoes are 
sequestered within a unique double membrane cytosolic vesicle, the autophagosome. Chaperone-
mediated autophagy involves direct translocation of unfolded substrate proteins across the 
lysosome membrane through the action of a cytosolic and lysosomal chaperone hsc70 and the 
integral membrane receptor LAMP-2A. (Mizushima et al., 2008). 
Macroautophagy 
Microautophagy 
 autophagy 
Chaperone-mediated 
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Characterization of molecular mechanisms involved in autophagy has been possible 
based on the identification of ~27 autophagy-related genes (ATGs) by yeast genetic 
screens (Klionsky et al., 2003). ATGs are involved in fundamental steps in autophagy, like 
signaling, autophagosome formation, transport and fusion with the vacuole, and bear a 
high similarity with the mammalian counterparts (Yorimitsu and Klionsky, 2005). ATGs are 
also involved in cytoplasm-to-vacuole targeting (Cvt), which transports inactive precursors 
of hydrolases from the cytoplasm to the vacuole where they are activated by the acidic pH 
(Khalfan and Klionsky, 2002).  
Several ATGs are essential for autophagy induction. Under nutrient availability conditions, 
TOR, a negative regulator of autophagy, inhibits formation of the Atg1 kinase complex by 
inducing the hypherphosphorylation of Atg13. As the binding affinity of Atg13 to Atg1 
decreases, the first step in autophagy induction is inhibited (Kamada et al., 2000). Under 
starvation conditions, Atg1 binds Atg13 and Atg17, forming a complex. Together with the 
sub-complex formed by Atg17, Atg31 and Atg29, the induction of autophagy is complete 
(Suzuki and Ohsumi, 2007). 
ATGs have an important role in the two conjugation systems involved in autophagosome 
formation, Atg12-Atg5 and Atg8-phosphatidylethanolamine. The Atg12-Atg5 conjugation 
system is required for the expansion of the autophagosomal membrane. Similarly to 
ubiquitination, Atg12 is conjugated to Atg5 by Atg7, an E1-like protein, and by Atg10, an 
E2-like protein (Mizushima et al., 1998). As part of the newly formed complex, Atg5 binds 
Atg16 for a complete activation (Kuma et al., 2002).  In the Atg8 conjugation system, Atg8 
is processed by Atg4 (Kirisako et al., 2000) and activated by Atg7, an E1-like protein. Atg3 
functions next as an E2 conjugation enzyme, rendering Atg8 able to interact with 
phosphatidyl-ethanolamine (PE). Upon this interaction, Atg8 changes conformation and 
acts on the dynamic of the autophagosomal membrane, necessary for autophagosome 
formation (Ichimura et al., 2000).  
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Autophagy is involved in cellular processes like development, adaptation to starvation, 
removal of damaged organelles and programmed cell death (Marino and Lopez-Otin, 
2008). Due to ist important role in cellular homeostasis, autophagy confers protection 
against progression of several human diseases like cancer, muscular disorders and 
neurodegeneration (Cuervo, 2004; Mizushima et al., 2004). 
 
1.4. α-synuclein degradation  
A central question for Parkinson’s disease remains α-synuclein degradation which has 
been investigatigated in cell culture PD models (Opazo et al., 2008; Riedel et al., 2010). 
Although the degradation route of α-synuclein in PD has not been fully elucidated, studies 
suggest that the protein can be cleared by both autophagic pathways and the UPS 
(Vogiatzi et al., 2008; Webb et al., 2003).  
 
1.4.1 The UPS in Parkinson’s disease 
There are several indications that defective proteasomal degradation is associated with α-
synuclein. One of them is the fact that the misfolded protein accumulates in LBs which 
were found ubiquitinated (Cookson et al., 2005).  
Apart from the ubiquitinated Lewy bodies, mutations in the E3 ubiquitin ligase Parkin and 
in the ubiquitin carboxy-terminal hydrolase L1(UCH-L1) cause some forms of inherited PD 
(Polymeropoulos et al., 1997), suggesting that a dysfunctional UPS contributes to the 
disease.  
According to several reports, α-synuclein may be degraded by the 26S proteasome 
(Bennett et al., 1999; Tofaris et al., 2001). On the other hand, α-synuclein does not appear 
to be targeted to the proteasome (Ancolio et al., 2000), but rather to inhibit it (Chen et al., 
2005; Lindersson et al., 2004). While it was already shown that proteasomal activity is 
decreased in PD (McNaught and Jenner, 2001), several groups observed that impairing 
the proteasome further enhances α-synuclein accumulation (Sharma et al., 2006; 
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Zabrocki et al., 2005). It is still under debate whether proteasomal inhibition in PD is due 
to α-synuclein accumulation or whether α-synuclein accumulation is caused by 
proteasomal malfunction. 
 
1.4.2 Autophagy and Parkinson’s disease 
Autophagic pathways may clear α-synuclein oligomeric species and aggregates which 
cannot be processed by the proteasome (Pan et al., 2008). It has also been proposed that 
once the proteasome becomes impaired, autophagy takes over α-synuclein degradation 
(Pandey et al., 2007; Rubinsztein, 2007).  
The involvement of autophagy in α-synuclein clearance is often investigated upon its up-
regulation or inhibition, commonly achieved by the drugs rapamycin and 3-Methyladenine 
respectively (Berger et al., 2006; Cuervo, 2008; Ravikumar et al., 2002). In cell culture 
models of PD, chemical inhibition of autophagy was shown to promote α-synuclein 
accumulation (Rott et al., 2008). Since autophagy inhibition was additionally shown to be 
more effective in preventing α-synuclein clearance than proteasomal inhibition, autophagy 
might be the predominant pathway of α-synuclein degradation (Rott et al., 2008). 
Supporting this conclusion, the autophagy-activating drug rapamycin was shown to 
stimulate α-synuclein clearance (Webb et al., 2003). 
In neuronal cells, α-synuclein was shown to be degraded via two autophagic routes, 
chaperone mediated autophagy and macroautophagy (Cuervo et al., 2004; Vogiatzi et al., 
2008). Additionally, an increased number of autophagic markers found in Parkinson 
patients (Anglade et al., 1997) suggests that autophagy might be up-regulated in 
response to α-synuclein accumulation. Autophagy up-regulation means an enhanced 
protein degradation which could protect neurons from α-synuclein toxicity. However, α-
synuclein can impair macroautophagy (Winslow et al., 2010) and trigger autophagic cell 
death (Stefanis et al., 2001), suggesting an interplay between α-synuclein and autophagy. 
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1.5. Aims of this study 
Based on the model introduced by Outeiro and Lindquist in 2003, many studies employ S. 
cerevisiae to investigate α-synuclein mechanisms of toxicity (Dixon et al., 2005; Fiske et 
al., 2011; Soper et al., 2011). Nevertheless, studies have been reporting inhibition of yeast 
growth despite lack of α-synuclein aggregation (Dixon et al., 2005), α-synuclein 
aggregation despite normal yeast growth (Zabrocki et al., 2005) or lack of both cytotoxicity 
and of aggregation (Fiske et al., 2011). Since different α-synuclein constructs are used 
and the amount of α-synuclein in the cell is usually not quantified, it is difficult to compare 
results.  The first question addressed by this study concerned the potential and the limits 
of yeast as a Parkinson’s disease model.  In a systematic analysis, a variety of α-
synuclein constructs with and without a fluorescent tag, containing various fluorescent 
markers at either termini and containing or lacking linker sequences were examined for 
their ability to aggregate and impair yeast growth.   
α-synuclein was previously shown to impair yeast growth and to form aggregates when 
integrated in two yeast genomic loci (Outeiro and Lindquist, 2003). On the other hand, 
normal yeast growth and only minimal intracellular aggregates were reported with high-
copy expression (Sharma et al., 2006). Considering the inconsistency in literature, the 
next question concerned the relevance of α-synuclein concentration for aggregation and 
growth impairment. A gene dosage analysis was performed to determine the threshold for 
α-synuclein aggregation and toxicity. The PD model characterized in the first part of the 
study was further employed to examine α-synuclein degradation pathways.    
A hallmark of PD is the progressive death of dopaminergic neurons in the cortical region 
of the brain while surviving neurons contain proteinaceous inclusions (Spillantini et al., 
1997). Another aim of this work was to investigate the ability of cells to cope with α-
synuclein inclusions. In this respect, promoter shut-off experiments addressed the 
potential of yeast cells to recover from α-synuclein toxicity and their ability to clear α-
synuclein accumulation. 
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Since α-synuclein has been proposed to be degraded by both the proteasome and 
autophagic pathways (Webb et al., 2003), a major objective of this study was to 
investigate which of the two systems is predominant in α-synuclein aggregate clearance. 
The involvement of the 26S proteasome as well as of autophagy and the vacuole in this 
process was analyzed through a chemical and a genetic approach. Chemical treatments 
with the proteasome-inhibitor MG132 and with the vacuolar protease inhibitor 
phenylmethanesulfonyl fluoride (PMSF) confirmed the data obtained with degradation-
related mutants covering proteasomal, vacuolar and autophagic defects. Autophagy 
involvement in α-synuclein aggregate clearance was further addressed by testing the 
effect of the autophagy-inducing drug rapamycin on α-synuclein aggregation.  
It has recently been suggested that α-synuclein can inhibit macroautophagy (Winslow et 
al., 2010). A final goal of this study was to analyze the regulation of yeast 
macroautophagy (further referred to as autophagy) in response to α-synuclein 
overexpression. Together with α-synuclein clearance data, this offered a new insight into 
the interplay between α-synuclein and autophagy in yeast.    
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2. MATERIALS AND METHODS  
 
2.1 Materials 
 
2.1.1. Yeast strains  
All S. cerevisiae strains used in this study are listed in Table 1. The yeast background 
generally employed for α-synuclein experiments was wild type W303-1A (EUROSCARF, 
Frankfurt, Germany). Several strains were constructed in this background by integrating 
the cDNA of the α-synuclein-encoding gene (SNCA) fused to GFP via linker in the triple-
mutated ura3-52 genomic locus. Strains with one, two and three tandemic integrations of 
wild type (WT) α-synuclein or α-synuclein mutants A30P and A53T were selected for 
analysis. The W303 background was also used for constructing TAP strains with two 
genomic integration of TAP-tagged WT α-synuclein at the C- and at the N-terminus. W303 
further served as parent strain for the temperature-sensitive proteasome mutant cim3-1, 
for the autophagy mutant Δatg1 and for the double mutant cim3-1Δatg1. The Δerg6 
(Δise1) mutant in the BY4741 genetic background (EUROSCARF, Frankfurt, Germany) 
was employed for drug-treatment experiments. BY4741 also served as background for 
Δpep4 and Δypt7 mutants. The diploid strain Sigma1278B was employed for experiments 
involving pseudohyphal growth.  
 
 
 
 
“We think in generalities, but we live in detail.” 
 
  Alfred North Whitehead  
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Table 1. Yeast strains used in this study. 
 
Strain 
 
Genotype 
 
Source 
 
W303-1A 
 
MATa; ura3-52; trp1D2; leu2-3_112; his3-11; ade2-1; can1-100 EUROSCARF 
RH3465 W303 containing GAL1::GFP in ura3 locus AG Braus 
RH3466 W303 containing 1 genomic copy of GAL1::SNCAWT::GFP in 
ura3 locus (KLID linker) 
AG Braus 
RH3467 W303 containing 2 genomic copies of GAL1::SNCAWT::GFP in 
ura3 locus (KLID linker) 
AG Braus 
RH3468 W303 containing 3 genomic copies of GAL1::SNCAWT::GFP in 
ura3 locus (KLID linker) 
AG Braus 
RH3469 W303 containing 1 genomic copy of GAL1::SNCAA30P::GFP in 
ura3 locus (KLID linker) 
This study 
RH3470 W303 containing 2 genomic copies of GAL1::SNCAA30P::GFP in 
ura3 locus (KLID linker) 
This study 
RH3471 W303 containing 3 genomic copies of GAL1::SNCAA30P::GFP in 
ura3 locus (KLID linker) 
This study 
RH3472 
 
W303 containing 1 genomic copy of GAL1::SNCAA53T::GFP in 
ura3 locus (KLID linker) 
This study 
RH3473 W303 containing 2 genomic copies of GAL1::SNCAA53T::GFP in 
ura3 locus (KLID linker) 
This study 
RH3474 W303 containing 3 genomic copies of GAL1::SNCAA53T::GFP in 
ura3 locus (KLID linker) 
This study 
RH3443 W303 containing 2 genomic copies of GAL1::SNCAWT::myeGFP 
in ura3 locus (AAAG linker) 
AG Braus 
RH3483 
 
W303 containing 2 genomic copies of GAL1::SNCAWT::TAP tag 
in ura3 locus (KLID linker) 
This study 
RH3484 
 
W303, containing 2 genomic copies of GAL1::TAP tag::SNCAWT 
in ura3 locus (KLID linker) 
This study 
RH3475 W303 with YGL180w::kanMX4 (Δatg1), GAL1::SNCAWT::GFP in 
his and trp genomic loci  
AG Braus 
RH3477 W303 with YGL180w::kanMX4, cim3-1, temperature sensitive 
(cim3-1Δatg1  double mutant), GAL1::SNCAWT::GFP in his and 
trp genomic loci 
AG Braus 
RH3486 W303 with cim3-1, temperature sensitive, GAL1::SNCAWT::GFP 
in his and trp genomic loci  
AG Braus 
HiTox 
 
W303 containing GAL1::SNCAWT::GFP in ura3 and trp1 genomic 
loci  
Outeiro and 
Lindquist, 2003 
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BY4741 MATa; his3Δ 1; leu2Δ0; met15Δ0; ura3Δ0 EUROSCARF 
Δerg6 BY4741; MATa; his3D1; leu2D0; met15D0; ura3D0; 
YML008c::kanMX4 
EUROSCARF 
Δpep4 BY4741; MATa; his3D1; leu2D0; met15D0; ura3D0; 
YPL154c::kanMX4 
EUROSCARF 
Δypt7 BY4741; MATa; his3D1; leu2D0; met15D0; ura3D0; 
YML001w::kanMX4 
EUROSCARF 
RH2447 Sigma1278B; MATa/α, ura3-52/ura3-52, leu2::hisG/LEU2, 
TRP1/trp1::hisG 
EUROSCARF 
 
2.1.2. Yeast plasmids 
All plasmids used in this study are listed in Table 2. WT, A30P or A53T α-synuclein cDNA 
sequences preceded by the GAL1 promoter and followed by the CYC1 terminator were 
cloned into the pRS426 high-copy expression plasmid and into the pRS306 integrative 
plasmid (Sikorski and Hieter, 1989). pRS426 additionally served as a vector for cloning 
the TP α-synuclein sequence (Karpinar et al., 2009). All plasmids contained an intact 
URA3 gene for selection. For microscopic studies α-synuclein and variants were tagged 
with GFP via linker (Outeiro and Lindquist, 2003), with monomeric enhanced GFP 
(myeGFP, Maeder et al., 2007) with and without linker, with mCherry via linker or with 
eGFP via linker. The cDNA of the human wild type SNCA gene fused via the KLID linker 
to GFP was amplified by PCR from the genomic DNA of the yeast strain HiTox (Outeiro 
and Lindquist, 2003). α-synuclein variants were tagged either at the N- or at the C- 
terminus. N-terminal fusions were connected by SAAAG linker and C-terminal fusions by 
either AAAG or KLID linkers. For TAP experiments integrative pRS306 plasmids were 
used containing a TAP tag (EUROSCARF) either at the N- or at the C-terminus of α-
synuclein, attached through the KLID linker. Autophagy-monitoring assays were 
performed with a pRS416 plasmid containing the chimeric fusion GFP-Atg8 under the 
copper-inducible promoter CUP1 (Cheong et al., 2005). A TRP1 gene on this plasmid 
served as selection marker. For experiments involving pseudohyphae induction α-
synuclein was placed under the CUP1 promoter in a pRS426 vector.  
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Table 2. Yeast plasmids used in this study. 
 
Plasmid Description Source 
 
pME2795 
 
pRS426-GAL1-promoter, CYC1-terminator, URA3, 2µm, pUC 
origin, AmpR 
 
AG Braus 
pME3760 pME2795 with GAL1::SNCAWT This study 
pME3761 pME2795 with GAL1::SNCAA30P This study 
pME3762 pME2795 with GAL1::SNCAA53T This study 
pME3941 pME2795 with GAL1::SNCAA30P/A56P/A76P AG Braus 
pME3526 pME2795 with GAL1::eGFP-SNCAWT  (SAAAG linker) AG Braus 
pME3527 pME2795 with GAL1::eGFP-SNCAA30P (SAAAG linker) AG Braus 
pME3528 pME2795 with GAL1::eGFP-SNCAA53T (SAAAG linker) AG Braus 
pME3759 pME2795 with GAL1::GFP AG Braus 
pME3763 pME2795 with GAL1::SNCAWT::GFP (KLID linker) AG Braus 
pME3764 pME2795 with GAL1::SNCAA30P::GFP (KLID linker) AG Braus 
pME3765 pME2795 with GAL1::SNCAA53T::GFP (KLID linker) AG Braus 
pME3942 pME2795 with GAL1::SNCAA30P/A56P/A76P::GFP (KLID linker) AG Braus 
pME3766 pME2795 with GAL1::SNCAWT::myeGFP (AAAG linker) AG Braus 
pME3943 pME2795 with GAL1::SNCAWT::GFP (AAAG linker) AG Braus 
pME3769 pME2795 with GAL1::SNCAWT::myeGFP (no linker) AG Braus 
pME3770 pME2795 with GAL1::SNCAA30P::myeGFP (no linker) AG Braus 
pME3771 pME2795 with GAL1::SNCAA53T::myeGFP (no linker) AG Braus 
pME3772 pME2795 with GAL1::SNCAWT::mCherry (KLID linker) AG Braus 
pME3773 pME2795 with GAL1::SNCAWT::myeGFP (KLID linker) AG Braus 
pME3774 pRS306-GAL1-promoter, CYC1-terminator, URA3, integrative, 
pUC origin, AmpR 
AG Braus 
pME3945 pME3774 with GAL1::SNCAWT::GFP (KLID linker) AG Braus 
pME3946 pME3774 with GAL1::SNCAA30P::GFP (KLID linker) AG Braus 
pME3947 pME3774 with GAL1::SNCAA53T::GFP (KLID linker) AG Braus 
pME3948 pRS416-CUP1-promoter, CYC1-terminator, TRP1, pUC origin, 
AmpR with GFP::Atg8 
Cheong et al., 
2005 
pME3780 pBS1479, plasmid for TAP-tagging of proteins at the C-terminus EUROSCARF 
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pME3781 pBS1761, plasmid for TAP-tagging of proteins at the N-terminus EUROSCARF 
pME3952 pME3774 with GAL1::SNCAWT::TAP tag(KLID linker) This study 
pME3953 pME3774 with GAL1::TAP tag::SNCAWT (KLID linker) This study 
pME3954 pRS426-CUP1-promoter, CYC1-terminator, URA3, 2µm, pUC 
origin, AmpR 
AG Braus 
pME3955 pME3954 with CUP1::SNCAWT This study 
pME3956 pME3954 with CUP1::SNCAA30P This study 
pME3957 pME3954 with CUP1::SNCAA53T This study 
 
2.1.3  Oligonucleotides 
The oligonucleotides with which the plasmids listed in Table 2 were prepared are given in 
Table 3. 
 
Table 3. Oligonucleotides used in preparing the plasmids in this study. 
 
Name 
 
Sequence (5’- 3’) 
 
Use 
 
NTTP68 
 
ATG TCT AAA GGT GAA GAA TTA TTC (24-mer) 
 
myeGFP forward primer   
NTTP69 TTA ACC CGG GGA TCC TTT GTA C (22-mer) myeGFP reverse primer 
NTTP70 CCC AAG CTT ATG GAT GTA TTC ATG AAA G 
(28-mer) 
SNCA forward primer 
containing HindIII site 
before start codon  
NTTP71 CCG CTC GAG TTA GGC TTC AGG TTC GTA G 
(28-mer) 
SNCA reverse primer 
containing XhoI restriction 
site after the stop codon  
NTTP77 CCC AAG CTT ATG TCT AAA GGT G (22-mer) Forward nested primer for 
the amplification of 
myeGFP-SNCA PCR 
fragment 
NTTP78 CCG CTC GAG TTA GGC TTC AGG (21-mer) Reverse nested primer for 
the amplification of 
myeGFP-SNCA PCR 
fragment 
NTTP79 GCT GCA TAA CCA CTT TAA CTA (21-mer) GAL1 forward primer used 
for sequencing  
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NTTP95 GCC ATA CCG TTA AAG AAG CAA GC (23-mer) Forward primer for 
amplifying the knock out 
cassette of atg1 
NTTP96 ATC TAA GTT AAT TGT CAT GTC GGA TC (26-
mer) 
Reverse primer for 
amplifying the knock out 
cassette of atg1 
NTTP127 CCG CTC GAG TCA TCA GTC GAG CTT GTA 
CAG CTC G (34-mer) 
Reverse primer for mCherry 
with XhoI restriction site and 
stop codon 
NTTP126 CCG CTC GAG TTA TTA AGA TCC TTT GTA CAA 
TTC ATC C (37-mer) 
Reverse primer for myeGFP 
with XhoI restriction site and 
stop codon 
NTTP128 CGG ACT AGT ATG GAT GTA TTC ATG AAA GG 
(29-mer) 
SNCA forward primer 
containing SpeI site before 
start codon 
DP1 AAA CTC GAG TCA GGT TGA CTT CCC C (25-
mer) 
Reverse primer for TAP tag 
with XhoI restriction site for 
C terminal TAP  
DP2 AAG CTT ATC GAT ATG GAA AAG AGA AGA 
TGG AAA AAG (36-mer) 
Forward primer for C-
terminal TAP starting with 
KLID linker sequence 
DP3 ATC GAT AAG CTT GGC TTC AGG TTC GTA 
GTC TTG (33-mer) 
Reverse primer for SNCA 
with KLID linker sequence 
at the end  
DP4 GGG ACT AGT ATG ATA ACT TCG TAT AGC 
ATA CAT TAT AC (38-mer) 
Forward primer for N-
terminal TAP tag with SpeI 
restriction site at the 
beginning  
DP5 TTT CCC GGG TTA GGC TTC AGG TTC GTA (27-
mer) 
Reverse primer for SNCA 
with XmaI restriction site at 
the end 
DP6 AAG CTT ATC GAT ATG GAT GTA TTC ATG AAA 
GGA C (34-mer) 
Forward primer for SNCA 
with KLID linker sequence 
at the beginning  
DP7 ATC GAT AAG CTT TAG GGC GAA TTG GGT 
ACC G (31-mer) 
Reverse primer for N-
terminal TAP tag with KLID 
linker sequence at the end 
 
 
Materials and Methods 
 
 
 
- 22 - 
 
2.2 Methods 
 
2.2.1 Molecular Biology methods 
2.2.1.1 DNA sequences  
All constructs used in this study were verified by DNA sequencing. Sequences were 
analyzed with the 4Peaks software (www.mekentosj.com) and the LASERGENE 
application of the DNASTAR software package.  
Yeast chromosomal sequences employed as templates for DNA amplification were 
analyzed using the tools available on the SGD (Saccharomyces genome database) 
website (www.yeastgenome.org).  
 
2.2.1.2 Polymerase Chain Reaction (PCR) 
DNA amplification was performed by PCR according to pre-established protocols (Saiki et 
al., 1988). Phusion polymerase (New England Biolabs, Frankfurt, Germany) was 
employed for cloning purposes and Taq polymerase (Fermentas, St.Leon-Rot, Germany) 
was employed for checking the correctness of the amplified sequences. PCRs performed 
with Phusion polymerase followed manufacturer’s instructions. For PCRs performed with 
Taq, the amplification program started with an initial denaturation step at 95°C for 2 min, 
followed by 31 cycles of denaturation at 95°C for 1 minute, annealing at different 
temperatures for 45 seconds and extension at 72°C for 1 min/kb. Annealing temperatures 
varied from 55°C to 65°C. The program ended with a final extension step at 72°C for 10 
min. All reactions were performed in Primus 96plus PCR cyclers (MWG-Biotech, 
Ebersberg, Germany). PCR products were purified using the QIAspin Gel Extraction Kit 
(Qiagen, Hilden, Germany). 
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2.2.1.3 Restriction digestions 
Digestions of PCR-amplified DNA sequences were performed with the appropriate 
restriction enzymes (Fermentas, St.Leon-Rot, Germany). Cloning vectors were digested 
with the same enzymes as the inserts. The reactions were incubated at 37°C for 2-3 hours 
then subjected to agarose gel electrophoresis. The restricted fragments were purified 
using the QIAspin Gel Extraction Kit (Qiagen, Hilden, Germany).  
 
2.2.1.4 Ligations 
Vectors were incubated with inserts in a molar ratio of 1:3.  Ligations were carried out by 
T4 DNA ligase (Fermentas, St.Leon-Rot, Germany) in 1xT4 DNA ligase buffer 
(Fermentas, St.Leon-Rot, Germany). The reactions were incubated at 16°C overnight and 
heat-inactivated at 65°C for 10 min. 
 
2.2.1.5 Transformation into chemically competent E. coli cells 
Escherichia coli (E. coli) DH5α competent cells (DSMZ, Braunschweig, Germany) were 
thawed on ice and 5 μl of the inactivated ligation reaction were added to 250 μl cells.  
After 30 min incubation on ice, the cells were subjected to heat shock at 42°C for 60 
seconds and placed back on ice for 5 min. 800 μl of SOC medium (SOB + 20 mM 
glucose) was added to the mixture, followed by incubation at 37°C for 1h with constant 
shaking. The cells were finally centrifuged at 2500 rpm for 3 min (Biofuge pico, Heraeus, 
Hanau, Germany) and plated on LB agar. Since the transformed plasmids carried an 
ampicillin resistance gene for selection, the agar plates contained ampicillin at a final 
concentration of 100 μg/ml. After 1 day incubation at 37°C, clones were picked and 
analyzed by PCR. The reaction was performed as previously described, with the 
exception that instead of a DNA template a bacterial clone was dissolved in the PCR 
mixture. Apart from colony PCR, clones were sequenced to ensure the presence and the 
right orientation of the insert. 
Materials and Methods 
 
 
 
- 24 - 
 
2.2.1.6 Plasmid isolation from E. coli 
E. coli colonies harboring plasmids of interest were inoculated in 5 ml LB medium 
supplemented with 100 μg/ml ampicillin and cultured at 37°C overnight. Cells were 
harvested by centrifugation at 13 000 rpm in a tabletop centrifuge (Biofuge pico, Heraeus, 
Hanau, Germany). Plasmid isolation was further carried out following the QIAprep Spin 
Miniprep kit and protocol (Qiagen, Hilden, Germany). Plasmid DNA was eluted in 50 μl 
water out of which 2 µl checked by agarose gel electrophoresis. In parallel, DNA 
concentrations were measured using the NanoDrop spectrophotometer (Thermo Fisher 
Scientific Inc., Waltham, MA, USA).  
 
2.2.1.7 Immunoblotting 
10 µg yeast protein were incubated with SDS loading buffer, denatured at 95°C and run 
on a 12% SDS polyacrylamide gel. Proteins were transferred on a nitrocellulose 
membrane by blotting for one hour at 100V. The membrane was blocked for one hour at 
room temperature in 5% non-fat milk solution then probed with a primary antibody at 4°C 
overnight. Primary antibodies used in this study are listed in Table 4. After several 
washes, the membrane was probed with a secondary antibody for two hours at room 
temperature. Peroxidase-coupled goat anti-mouse or goat anti-rabbit immunoglobulins G 
served as secondary antibodies (1:5000, Invitrogen, Karlsruhe, Germany). The membrane 
was washed several times and incubated with reagents from the Immobilon Western 
Chemiliminiscent HRP Substrate detection kit (Millipore, Schwalbach, Germany) then 
exposed to ECL film (GE Healthcare Limited, Buckinghamshire, UK) in the dark. The film 
was developed in the PROTEC Processor Compact film-developing machine (Siemens, 
Erlangen, Germany). In parallel, the signal was analyzed using the QUANTUM ST4-3000 
gel documentation system equipped with the BIO-1D advanced analysis software (Vilber 
Lourmat, Eberhardzell, Germany).  
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Table 4. Primary antibodies used in this study. 
 
Antibody 
 
Animal 
 
Type 
 
Dilution 
 
Source 
 
anti-α-synuclein 
 
mouse 
 
monoclonal 
 
1:3000 
 
AnaSpec, Fremont, CA, USA 
 
anti-α-synuclein 
 
rabbit 
 
ployclonal 
 
1:500 Santa Cruz Biotechnology,   
CA, USA 
anti-GFP mouse monoclonal 1:500 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA 
anti-ubiquitin mouse monoclonal 1:1000 Millipore, Billerica, MA, USA 
anti-Smt3 rabbit polyclonal 1:1000 LifeSpan Biosciences, Seattle, 
WA, USA 
anti-3-nitrotyrosine mouse monoclonal 1:1400 abcam, Cambridge, UK 
 
2.2.1.8 Southern hybridization  
To verify the integration of α-synuclein constructs into the ura3-52 mutated genomic locus 
of W303 yeast, several transformants were analyzed by Southern hybridization (Southern, 
1975). 10 µg of isolated genomic DNA were subjected to overnight restriction digestion 
with HindIII (Fermentas, St.Leon-Rot, Germany), and the restriction fragments were 
resolved on a 1% agarose gel. The gel was washed in 0.25 M HCl for 10 min, in 0.5 M 
NaOH/1.5 M NaCl for 25 min and finally in 1.5 M NaCl/0.5 M Tris for 30 min. The DNA 
was transferred on a nitrocellulose membrane (Pall, Dreieich, Germany) during three-hour 
blotting. After washing and drying the membrane, the DNA was crosslinked by UV 
irradiation for 5 min. Hybridization with the DNA probe was done overnight at 55°C. To 
prepare the hybridization probe, 100 ng of DNA corresponding to a URA3 gene fragment 
were denatured at 95°C and labeled with horseradish peroxidase using the ECL Direct 
Labeling and Detection System (GE Healthcare Limited, Buckinghamshire, UK). After 
several washing steps, the membrane was incubated with detection solution (GE 
Healthcare Limited, Buckinghamshire, UK) and exposed to ECL film (GE Healthcare 
Limited, Buckinghamshire, UK) in the dark. The film was developed in the PROTEC 
Processor Compact film-developing machine (Siemens, Erlangen, Germany). 
Materials and Methods 
 
 
 
- 26 - 
 
Multiple genomic integrations of α-synuclein constructs were estimated with the ImageJ 
software (Abramoff et al., 2004). One copy of the construct corresponded to the 2.7kb + 
4.7kb fragments, two copies corresponded to the 2.7kb + 4.7kb + 6.2kb fragments and 
three copies corresponded to the 2.7kb + 4.7kb + 6.2kb fragments, where the 6.2kb band 
had a higher intensity. 
 
2.2.2. Yeast methods  
2.2.2.1 Growth conditions  
Yeast cells harboring α-synuclein constructs were typically cultured at 30°C in selective 
synthetic complete (SC) medium (Guthrie and Fink, 1991) lacking uracil (-ura). For growth 
without α-synuclein induction, the SC medium contained 2% raffinose. To induce the 
GAL1 promoter of α-synuclein, the SC medium contained 2% galactose. Typically, cells 
growing overnight in rafinose medium were shifted to galactose medium at an OD600 of 
0.1. For promoter shut-off experiments, cells growing in raffinose medium overnight were 
transfered to galactose for 2 or 4h then shifted to SC medium supplemented with 2% 
glucose. For experiments involving pseudohyphae induction in diploid yeast, solid SLAD 
medium containing 0.17% Yeast Nitrogen Base without amino acids and ammonium 
sulfate, 50 µM ammonium sulfate, 2% glucose and 2% Bacto-agar (Gimeno et al., 1992) 
was employed. Additionally, to induce the CUP1 promoter of α-synuclein, the SLAD 
medium was supplemented with 10 µM CuSO4. For autophagy-monitoring assays, cells 
harboring both α-synuclein and GFP-Atg8 plasmids were grown in SC medium lacking 
uracil and tryptophan. The CUP1 promoter of GFP-Atg8 was induced with 50 µM CuSO4. 
All strains were cultured at 30°C, except for temperature-sensitive mutants cim3-1 and 
cim3-1Δatg1, which were grown and induced to express α-synuclein at 25°C. The cim3-1 
mutation was induced by shifting the cells from 25°C to 37°C. For experiments with these 
mutants, control strains were cultivated under the same conditions for consistency. In 
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autophagy-monitoring assays with cim3-1, cells were grown overnight at 25°C and 
transferred to 37°C concomitantly with α-synuclein induction. 
 
2.2.2.2 Yeast transformation  
Yeast transformations were performed according to standard protocols (Gietz et al., 
1992). Yeast cells were grown in 10 ml nutrient-rich YPD medium (Guthrie and Fink, 
1991) overnight. Cultures were centrifuged for 3 min at 3000 rpm (Sigma 4K15C, Sigma 
Laboratory Centrifuges, Osterode am Harz, Germany) and cells were resuspended in 10 
ml 100mM LiOAc/TE (5 ml 1M Tris-Cl pH 8.0, 1 ml 0.5 M Na-EDTA pH 8.0, 100 mM 
LiOAc in a total volume of 50 ml H2O). After two washes in LiOAc/TE, cells were 
competent for transformation. 20 μl carrier (salmon sperm) DNA and 5 µl of a 
concentrated 2µ plasmid suspension were added to 200 μl competent yeast cells together 
with 800 μl of 50% polyethylene glycol (PEG) in LiOAc. For transformations targeting the 
ura3 genomic locus, the plasmids were integrative thereby requiring linearization prior to 
transformation. 10 ng plasmid DNA was thus digested for 2h at 37°C with StuI 
(Fermentas, St.Leon-Rot, Germany)  for SNCA-GFP integration, with EcoRV (Fermentas, 
St.Leon-Rot, Germany) for SNCA-TAP tag integration and with Bsp119I (Fermentas, 
St.Leon-Rot, Germany) for TAP tag-SNCA integration. Cells were incubated with the 
particular plasmids on a shaking platform at 30°C for 30 min. Subsequently, cells were 
subjected to heat shock at 42°C for 20 min. After a short centrifugation at 4000 rpm, the 
cell pellet was resuspended in 1 ml YPD medium and incubated at 30°C for 1h. Cells were 
finally centrifuged at 4000 rpm for 1 min and plated on SC-ura solid medium, as the 
transformed plasmids carried a URA3 auxotrophic marker. For the co-transformation of α-
synuclein and GFP-Atg8 plasmids, cells were plated on solid medium lacking both uracil 
and tryptophan as selection markers. After 2-4 days incubation at 30°C or at 25°C in the 
case of temperature-sensitive mutants, colonies were selected and restreaked.  
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2.2.2.3 Spotting tests 
To assess yeast growth on solid medium, cells were grown to mid-log phase in SC 
medium containing raffinose and lacking uracil. Cells were 10-fold serially diluted starting 
with an OD600 of 0.1 and spotted on SC-ura agar plates containing either 2% glucose or 
2% galactose. The plates were incubated at 30°C for 2 days then photographed. 
 
2.2.2.4 Prepraration of yeast crude extracts     
Yeast cultures were grown overnight in synthetic complete medium containing 2% 
raffinose and lacking uracil. For induction of the GAL1 promoter, cells were inoculated in 
50 ml SC-ura with galactose to an OD600 of 0.1 and further incubated for 6h. Cells were 
collected by centrifugation at 4000 rpm for 3 min, washed with TE buffer (10 mM Tris-Cl 
pH 7.5/8.0, 1 mM EDTA, pH 8.0), and resuspended in 200 μl of R-buffer (150 μl 1M Tris 
pH 7.5, 6 μl 0.5 M EDTA, 150 μl 1M DTT, 120 μl PIM complete (Roche, Mannheim, 
Germany). Cells mixed with 0.45 mm glass beads were mechanically broken by vigorous 
vortexing for 10 min at 4°C. Crude cell extracts were obtained by centrifugation at 13 000 
rpm for 10 min at 4°C (Biofuge fresco, Heraeus, Hanau, Germany). The supernatants 
were collected and protein concentrations were determined in a Bradford assay (Bradford, 
1976).  
 
 2.2.2.5 Isolation of yeast DNA 
Isolation of genomic DNA from S. cerevisiae was performed according to standard 
procedures (Hoffman and Winston, 1987). Cells growing overnight in 10 ml YPD medium 
at 30°C were collected by centrifugation and shortly washed. 200 µl breaking buffer (2% 
V/V TritonX 100, 1% V/V SDS, 100 mM NaCl, 10 mM Tris-Cl, pH 8.0, 1 mM EDTA, pH 
8.0), 200 µl Phenol:Chloroform:Isomyl (25:24:1)  and 0.45 mm glass beads were added to 
the cell pellet. Cells were mechanically broken by rigorous vortexing for 10 min at 4°C 
then centrifuged at 13 000 rpm for 5 min. The supernatant was collected and mixed with 1 
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ml cold ethanol for DNA precipitation. After a short centrifugation step the pellet was 
incubated with 400 µl TE buffer (10 mM Tris-Cl pH 7.5/8.0, 1 mM EDTA, pH 8.0) and 3 μl 
RNase at 37°C for one hour. 1 ml cold etanol was added and the samples were 
centrifuged at 13 000 rpm for 5 min. The DNA pellet was dried at room temperature and 
dissolved in 50 µl TE buffer. 2 µl of the DNA suspension were verified by agarose gel 
electrophoresis.  
 
2.2.2.6 Promoter shut-off  
W303 cells harboring three genomic integrations of WT α-synuclein were grown overnight 
in raffinose then incubated in galactose for either two or four hours. To shut off the GAL1 
promoter, cells were transfered to glucose. In combined promoter shut-off and drug-
treatment experiments, W303 cells expressing α-synuclein from a high-copy vector were 
pre-incubated in galactose for 4h then shifted to glucose supplemented with the 
corresponding drugs at pre-established concentrations (Lee and Goldberg, 1996). For 
promoter shut-off analysis of degradation-related mutants, W303 and BY4741 wild type 
strains and Δatg1, cim3-1, cim3-1Δatg1 and Δpep4 mutants were employed. α-synuclein 
was overexpressed from a 2µ plasmid to achieve higher aggregation levels. Temperature-
sensitive mutants cim3-1 and cim3-1Δatg1 were grown overnight at 25°C and induced to 
express α-synuclein for 3h at 25°C and for 1h at 37°C. The temperature shift was 
necessary to induce the cim3-1 mutation. Promoter shut-off and subsequent growth was 
carried out at 37°C. For consistency, the parent strain W303 and the Δatg1 mutant were 
grown under the same conditions. Experiments with BY4741 and Δpep4 cells were 
performed at 30°C. Cells were observed by fluorescence microscopy before and after 
promoter shut-off and percentages of cells with aggregates were calculated.  
 
 
 
Materials and Methods 
 
 
 
- 30 - 
 
2.2.2.7 Autophagy monitoring assays 
W303 yeast cells were co-transformed with pCu416GFP-Atg8 (Cheong et al., 2005) and 
with pRS426 plasmids carrying α-synuclein. Cells grown overnight at 30°C in SC medium 
containing raffinose and lacking uracil and tryptophan were induced for 2h with 50 µM 
CuSO4 to produce GFP-Atg8. Cells were washed twice, diluted to an OD600 of 0.5 and 
incubated in 50 ml SC medium containing galactose and lacking uracil and tryptophan. 
From 10 ml culture collected at 2, 4 and 8h of induction cell extracts were prepared and 
subjected to immunoblotting as described. To induce autophagy, at the 4h time point of α-
synuclein induction, cells were washed twice and transferred to nitrogen starvation 
medium, SD(-N) (Takeshige et al., 1992), prepared with galactose. Probes were taken at 
2 and 4h after the shift and analyzed by western hybridization.  
 
2.2.3 Imaging methods 
2.2.3.1 Fluorescence microscopy and quantifications 
Yeast cultures were grown in synthetic complete medium containing raffinose and lacking 
uracil until mid-log phase then transferred to galactose medium for α-synuclein induction. 
Cells were visualized at different time points of induction using a Zeiss Axiovert S100 
microscope (Zeiss, Göttingen, Germany). Images were aquired with either a CoolSnap 
camera or with a QuantEM camera (Photometrics, Tucson, AZ, USA) and the spinning-
disc function at a 100x magnification. Depending on the fluorescent marker employed, a 
GFP or a dsRed filter was used. The images were analyzed with the SlideBook3I software 
(Intelligent Imaging Innovations, Göttingen, Germany).   
To quantify α-synuclein aggregation a minimum of 100 cells were counted per sample. 
The percent of cells with aggregates was determined by reporting the number of cells 
displaying cytoplasmic foci to the total number of cells counted. These included cells 
exhibiting only bright peripheral halos (plasma membrane localization), perivacuolar 
fluorescence and cytoplasmic distribution of the fluorescent signal. 
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2.2.3.2 Immunofluorescence 
Cultures of W303 cells transformed with high-copy plasmids containing WT, A30P or 
A53T α-synuclein were grown overnight in synthetic complete medium containing 2% 
raffinose and lacking uracil. For α-synuclein induction, cells were inoculated in SC medium 
containing 2% galactose and lacking uracil to an OD600 = 0.1. After 6h incubation, cells 
were collected, washed and fixed with 37% formaldehyde for 30 min. Cell walls were 
digested with 20 mg/ml zymolase, and the resulting protoplasts were permeabilized in 
0.5% Triton X-100 phosphate buffer. After 1h preblocking with 5% fetal bovine serum, 
protoplasts were incubated overnight with a mouse anti-α-synuclein antibody (1:3000, 
AnaSpec, Fremont, CA, USA). The protoplasts were washed and a donkey anti-mouse 
Alexa Fluor 594(red)-conjugated secondary antibody (1:200, Invitrogen, Karlsruhe, 
Germany) was applied. The samples were fixed and microscopically observed with a 
dsRed fluorescence filter as described.   
 
2.2.3.3 FM4-64 stainings 
Cells were grown in raffinose and induced in galactose medium to express GFP-tagged α-
synuclein. To demonstrate co-localization of the protein with endosomal vesicles and with 
the vacuolar membrane, cells were stained with the FM4-64 red-fluorescence dye (Vida 
and Emr, 1995). After two hours of α-synuclein induction, cells were treated with FM4-64 
at a final concentration of 1 nM. After 20 min incubation in the dark, cells were washed, 
resuspended in galactose medium and microscopically observed with a dsRed filter for 
the dye and a GFP filter for the tagged α-synuclein. Merged images were acquired. 
   
2.2.3.4 Light microscopy and colony formation quantification  
W303 cells harbouring two genomically-integrated copies of A53T α-synuclein were pre-
grown in raffinose then diluted to an OD600 of 0.1 in galactose. After 8h of α-synuclein 
induction, cells were 10-fold serially diluted starting with an OD600 of 0.1 and plated on 
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solid YPD medium containing glucose. Cells were observed at several time points after 
plating with an Olympus SZX12 light microscope (Olympus, Essesx, UK). Colony 
formation was quantified by reporting the number of cells forming colonies to the total 
number of cells. A colony was defined as a group of five or more cells. 
 
2.2.4 Drug treatments 
2.2.4.1 Inhibition of cellular degradation systems 
Drug treatments were applied to W303 cells concomitantly with transfer to glucose in 
promoter shut-off experiments. Carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132) 
(SIGMA-ALDRICH, Steinheim, Germany) dissolved in dimethylsulfoxide (DMSO) was 
supplemented to the cell suspension to a final concentration of 50 µM. W303 cultures 
treated with 0.1% DMSO served as control. Phenylmethanesulfonyl fluoride (PMSF) 
(ROTH, Karlsruhe, Germany) dissolved in ethanol (EtOH) was added to the cell 
suspension at a final concentration of 1 mM. W303 cultures treated with 1% EtOH served 
as control. The concentrations of drugs and solvents followed pre-established protocols 
(Lee and Goldberg, 1996).  
MG132 and PMSF treatments were also applied to W303 cells growing in galactose. For 
control, cells were treated with the respective solvent. Besides single-drug treatments, 
cells were also treated with both drugs simultaneously. For control, cells were treated with 
both solvents. Drugs and solvents were applied as described (Lee and Goldberg, 1996). 
 
 2.2.4.2 Rapamycin treatments  
Several concentrations of rapamycin (Merck KGaA, Darmstadt, Germany), including 20, 
50 and 100 nM, were initialy tested on W303 cells expressing α-synuclein from two 
genomic loci (HiTox strain, Outeiro and Lindquist, 2003). Next, cells expressing α-
synuclein from two genomic copies or overexpressing the protein were subjected to three 
scenarios of rapamycin treatment: pre-treatment, treatment at the same time with α-
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synuclein induction and treatment after α-synuclein induction. For pre-treatment, cultures 
were incubated in raffinose medium overnight and 1h before α-synuclein induction 
rapamycin was added to the medium. Cells were then washed and transferred to 
galactose medium. For treatment and induction, cells grown in raffinose were shifted to 
galactose medium supplemented with 100 nM rapamycin. For treatment after induction, 
cells were induced for 3h in galactose then the medium was supplemented with 100 nM 
rapamycin. Cells were visualized at different time points of α-synuclein induction. 
Aggregation percentages were recorded and compared. 
 
2.2.5 Protein purification methods 
2.2.5.1 Tandem Affinity Purification (TAP) 
A TAP tag (EUROSCARF, Frankfurt, Germany) was fused to the C- or N- terminus of α-
synuclein and cloned into the pRS306 integrative plasmid. Upon transformation, W303 
strains harboring two genomic integrations of the TAP-tagged α-synuclein constructs were 
selected. TAP followed a pre-established protocol (Puig et al., 2002). 100 ml pre-culture of 
each strain was inoculated into an overnight 2 liter culture in galactose medium. Cells 
were harvested in a 10 minute centrifugation at 4000 rpm at 4°C. All further steps were 
performed at 4°C. Cells were resuspended in 20 ml NP-40 buffer (15 mM Na2HPO4, 10 
mM NaH2PO4-H2O, 1.0% NP-40, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 0.1 mM 
Na3VO4) and mechanically broken by vortexing with glass beads for 10 min. After 5 min 
centrifugation at 2500 rpm, the supernatants were subjected to ultracentrifugation at 40 
000 rpm in a TH-641 swinging bucket rotor (Thermo Fisher Scientific Inc., Waltham, MA, 
USA) for 1,5 hours. Protein extracts were incubated for three hours on IgG Sepharose 6 
Fast Flow beads (Invitrogen, Karlsruhe, Germany) on a rotating platform. Lysates were 
incubated with tobacco etch virus (TEV) protease overnight then eluted. The eluates were 
further incubated with calmodulin beads (Invitrogen, Karlsruhe, Germany) for one hour 
and eluted in EGTA-containing buffer.  Protein samples were precipitated with 25% 
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trichloroacetic acid (TCA) on ice for 30 min. After centrifugation at 13 000 rpm for 30 min 
and two washing steps with acetone, the pellets were vacuum dried at 60°C using the 
Savant SPD11V SpeedVac Concentrator (Thermo Fisher Scientific Inc., Waltham, MA, 
USA). The pellets were resuspended in SDS loading buffer, denatured at 95°C and 
resolved on a 12% SDS polyacrylamide gel. Coomassie staining was next performed 
(Neuhoff et al., 1988) and the stained protein bands were tryptically digested (Shevchenko 
et al. 1996). Tryptic peptides extracted from each gel piece were separated using the 
ultimate HPLC system (Dionex, Amsterdam, Netherlands) and subjected to electrospray 
ionization mass spectrometry using the LCQ DecaXP machine (Thermo Electron Corp., 
San Jose, CA, USA).  
 
2.2.5.2 Co-immunoprecipitation 
W303 cells expressing α-synuclein overnight were harvested and broken by vortexing with 
glass beads in NP-40 buffer (also used in TAP). Lysates were clarified in a 10 minute 
centrifugation step at 13 000 rpm. Supernatants were incubated with a rabbit anti-α-
synuclein antibody (1:500, Santa Cruz Biotechnology, CA, USA) for one hour at 4°C then 
with Protein G Sepharose beads (Invitrogen, Karlsruhe, Germany) for two additional 
hours. After three washing steps, samples were incubated with SDS loading buffer at 
95°C and analyzed on a 12% SDS polyacrylamide gel. The gel was Coomassie stained 
and the stained protein bands were subjected to tryptic digestion and mass spectrometry.  
 
2.2.5.3 Purification of GFP-tagged α-synuclein by GFP-Trap_A  
W303 cells expressing GFP-tagged α-synuclein overnight were harvested and 
mechanically broken by vortexing with glass beads in NP-40 buffer (also used in TAP). 
Lysates were clarified in a 10 minute centrifugation at 13 000 rpm. Subsequent steps were 
performed according to the GFP-Trap protocol (chromotek, Martinsried, Germany). GFP-
Trap_A beads coated with anti-GFP antibodies were incubated with the clear cell lysates 
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for two hours at 4°C on a rotating platform. The beads were washed twice, resuspended 
in SDS loading buffer, boiled at 95°C for 10 min and sedimented at 300 rpm. The 
supernatants were resolved on a 12% SDS polyacrylamide gel. Protein bands were 
Coomassie stained and subjected to mass spectrometry as descriebed. 
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3. RESULTS 
 
3.1. The yeast model for α-synuclein aggregation and toxicity  
 
3.1.1 α-synuclein overexpression impairs yeast growth 
α-synuclein has been expressed in many model systems to reconstruct a Parkinson-like 
scenario that facilitates the investigation of PD cytotoxic mechanisms. The pathobiology of 
α-synuclein is also reproducible in the yeast Saccharomyces cerevisiae. Toxicity of 
heterologously expressed α-synuclein was questioned here according to the ability of the 
protein to impair yeast growth. The cDNA of the α-synuclein-encoding gene sequence, 
further denoted SNCA, was cloned into a high-copy yeast vector (2µ) under the control of 
galactose-inducible promoter GAL1. Growth of wild type W303 haploid yeast cells was 
compared in the presence and absence of α-synuclein at the ambient yeast growth 
temperature of 30°C both on solid medium and liquid culture.  
Overexpression of α-synuclein caused severe growth reduction for cells producing wild 
type (WT) and A53T versions, had a mild inhibitory effect on cells producing the A30P 
variant and led to uninhibited growth for cells expressing the triple proline (TP) mutant. In 
comparison, control cells expressing the empty vector grew uninhibited (Figure 7A).  
When modelling α-synuclein toxicity in yeast, different yeast strains could respond 
differently to α-synuclein overproduction. To check for possible background effects, the 
haploid strain BY4741 was employed for comparison. WT and A53T α-synuclein 
overexpressed here impaired growth, while the effect of A30P α-synuclein on BY4741 was 
only partial (Figure 7B). These results were similar to those obtained in the W303 
 
“Each problem that I solved became a rule, which served 
afterwards to solve other problems.” 
 
                                                               Rene Descartes  
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background and suggested that yeast genetic background does not affect α-synuclein 
toxicity. W303 cells were employed for further experiments. 
 
                                  A 
 
              
 
Figure 7. α-synuclein inhibits yeast growth. Spotting analyses. (A) W303 and (B) BY4741 yeast 
cells were transformed with a high-copy plasmid carrying wild type (WT), A30P, A53T or triple 
proline (TP) α-synuclein under the control of GAL1 promoter. Tenfold serially-diluted cells were 
spotted on inducing (galactose) and non-inducing (glucose) solid medium. Cells expressing the 
empty high-copy vector served as control. The plates were incubated at 30°C for 2 days then 
photographed.  
 
3.1.2 α-synuclein overexpression inhibits pseudohyphae 
formation in diploid yeast 
 
To further study the toxicity of α-synuclein on yeast growth, the effect of α-synuclein 
overexpression on pseodohyphal development was questioned. The diploid yeast strain 
Sigma1278B is able to form pseudohyphae under nitrogen starvation conditions. This can 
be achieved by providing the cells with a prefered fermentable carbon source (glucose) 
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CUP1 SNCA 
 Vector     WT     A30P    A53T   
SLAD+10 µM CuSO4 
Sigma1278B 
SLAD, no α-synuclein induction 
and a decreased nitrogen supply, e.g. by plating them on SLAD medium with 50 µM 
ammonium sulfate (Gimeno et al., 1992).  
Previously used GAL1-controlled α-synuclein constructs could not be used for this 
experiment because the GAL1 promoter is repressed in the presence of glucose (Traven 
et al., 2006) necessary for growth during nitrogen starvation. α-synuclein was therefore 
placed under a copper-inducible promoter, CUP1, and overexpressed in nitrogen-starved 
Sigma cells (Figure 8). To induce the promoter, several CuSO4 concentrations were 
preliminary tested. The optimal CuSO4concentration which did not affect pseudohyphal 
development of control cells and at the same time allowed for sufficient α-synuclein 
expression was 10 µM.  
 
 
 
 
                        
 
Figure 8. α-synuclein inhibits pseudohyphae development. Sigma1278B yeast cells were 
transformed with high-copy plasmids harboring WT, A30P or A53T α-synuclein under CUP1 
promoter. Cells were plated on SLAD medium supplemented with 10 µM CuSO4 to induce the 
promoter and photographed after two days. Cells expressing the empty vector served as control.  
 
Under these conditions, cells expressing WT α-synuclein or variants presented few and 
abnormal pseudohyphae. Control cells which did not express α-synuclein developed 
pseudohyphae normally. This suggested that an additional consequence of α-synuclein 
overexpression in yeast is impairment of pseudohyphal development.   
 
3.1.3 C-terminally tagged α-synuclein is cytotoxic and aggregates 
In order to visualize α-synuclein in living cells and to follow its localization throughout time, 
fluorescent tags are necessary. α-synuclein-GFP fusions had already been applied in 
previous PD studies, yet with contradictory results. Since the attachment of a fluorescent 
Results 
 
 
 
- 39 - 
 
tag poses the risk of interference with the protein’s natural behavior, derermining the 
requirements for functional α-synuclein-GFP constructs was mandatory.  
In the past, it has been observed that C-terminally GFP-tagged α-synuclein affected yeast 
growth in the same manner as untagged α-synuclein versions (Outeiro and Lindquist, 
2003). These results were also tested here with high-copy vectors carrying α-synuclein- 
GFP sequences connected via a linker (KLID). Cells expressing GFP-tagged WT and 
A53T α-synuclein presented growth inhibition (Figure 9). In comparison, the growth deficit 
of cells producing GFP-tagged A30P α-synuclein was milder. TP α-synuclein-GFP 
remained untoxic, similarly to the untagged version. The data suggested that attachment 
of a C-terminal tag does not interfere with the natural ability of α-synuclein to compromise 
cell growth.  
 
                                             
   
  
 
 
 
 
Figure 9. C-terminally tagged α-synuclein inhibits yeast growth. Spotting analysis. W303 yeast 
cells were transformed with a high-copy plasmid carrying WT, A30P, A53T or TP α-synuclein 
followed by linker (KLID) and GFP under the control of GAL1 promoter. Tenfold serially-diluted 
cells were spotted on inducing and non-inducing solid medium. Cells transformed with a plasmid 
carrying GFP downstream the GAL1 promoter served as control. Plates were incubated at 30°C for 
2 days then photographed.  
 
 
To inspect α-synuclein aggregation, the localization of the protein was monitored by live-
cell fluorescence microscopy in a time-course experiment. After an initial localization at 
the plasma membrane, GFP-tagged WT, A30P and A53T α-synuclein formed cytoplasmic 
inclusions further referred to as aggregates. In contrast, GFP-tagged TP remained 
distributed throughout the cytoplasm and did not aggregate (Figure 10A). 
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Aggregates were well defined already after 2h of induction and appeared to increase in 
size throughout time. Proportional with larger inclusions, cells displayed less fluorescence 
intensity at the plasma membrane, suggesting that as it starts aggregating, α-synuclein 
dissociates from the plasma membrane to accumulate in the cytoplasm.  
 
A                                                                           
 
Figure 10. C-terminally tagged α-synuclein forms aggregates. (A) Live-cell fluorescence 
microscopy of W303 yeast cells expressing α-synuclein-GFP connected via KLID linker from a 
high-copy plasmid. Cells expressing GFP were used as a control. Cells were pre-grown in non-
inducing medium to mid-log phase, transferred to inducing medium and visualized at 2, 4 and 8 
hours of induction. The aggregates of untagged WT, A30P and A53T α-synuclein were visualized 
by immunofluorescence (IF). Uninduced W303 cells were used for IF control. The white arrows 
indicate cytoplasmic inclusions. (B) Aggregation quantification. Columns represent the average 
aggregate percentage values of three independent experiments.  
 
Aggregation kinetics revealed that the percentage of cells containing aggregates 
increased over time (Figure 10B). At 8h of induction the population of cells displaying WT 
or A53T α-synuclein aggregates reached 80% whereas the aggregation percentage of 
A30P α-synuclein-expressing cells was only 35%. At 24h of induction the aggregation 
percentage of WT and A53T α-synuclein-expressing cells was 100%. At the same time 
point, the aggregation percentage of cells expressing A30P was reduced to 12%, 
suggesting that this mutant forms aggregates only transiently.  
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To ensure that the aggregate-formation ability of the three α-synuclein versions is not a 
GFP artifact, imunofluorescence (IF) was performed. W303 cells expressing untagged 
WT, A30P and A53T α-synuclein were permeabilized and incubated with an anti-α-
synuclein antibody subsequently bound by an Alexa Fluor-conjugated secondary 
antibody. Since the Alexa fluorophore is able to emit red fluorescence, a red signal is 
visible by fluorescence microscopy at the sites where the antibody has bound. All three 
untagged α-synucleins displayed red foci (Figure 10A), confirming the same aggregation 
patterns as the GFP-tagged counterparts.  
The fact that the α-synucleins which inhibited growth were also able to aggregate 
suggested a link between α-synuclein cytotoxicity and aggregation. 
 
3.1.4 Nature of fluorescent tag and of linker does not alter α-
synuclein toxicity or aggregation 
 
The possibility that a specific tag might be responsible for influencing α-synuclein 
aggregation or the protein’s ability to impair yeast growth was excluded by proving that the 
combination linker-tag tolerates exchanges. To this aim, several constructs were made by 
keeping the WT α-synuclein-KLID sequence and replacing the GFP with myeGFP or with 
mCherry. To show that the linker sequence does not interfere with α-synuclein’s behavior, 
an additional construct was tested, keeping the WT α-synuclein and the GFP sequence 
and exchanging the KLID linker by an AAAG linker (Figure 11).  
These constructs were compared based on α-synuclein toxicity and aggregation ability. As 
demonstrated by a spotting analysis, cells overexpressing any of the differently tagged α-
synucleins were unable to grow (Figure 11A), which suggested that all tags and linkers 
had the same effect in preserving α-synuclein ability to inhibit growth. 
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A                                                                  
 
B                                                                      C 
Figure 11. Different C-terminal tags connected to α-synuclein via linker result in similar 
toxicity and aggregation. (A) Construct schemes and spotting analysis. Cells were transformed 
with a high-copy plasmid carrying GAL1-controlled WT α-synuclein C-terminally fused to GFP, 
myeGFP or mCherry via the KLID linker and fused to GFP via the AAAG linker. Cultures were pre-
grown in non-inducing medium to mid-log phase, serially-diluted tenfold and spotted on inducing 
and non-inducing medium. After incubation at 30°C for 2 days the plates were photographed. Cells 
overexpressing GFP served as control. (B) Live-cell microscopy of yeast cells expressing WT α-
synuclein tagged with GFP, myeGFP and mCherry. Cells were pre-grown in non-inducing medium 
to mid-log phase, transferred to inducing medium and visualized at 2, 4 and 8h of induction. 
Cytoplasmic inclusions are indicated by white arrows. (C) Aggregation quantification. The column 
bars represent the percentages of cells with cytoplasmic inclusions as average values of three 
independent experiments.  
 
In addition, all constructs gave rise to aggregates (Figure 11B). Nevertheless, aggregates 
differed in morphology and accumulation kinetics. While GFP and mCherry α-synuclein 
aggregates were prominent and formed with a fast kinetic reaching 80-90% of cells in the 
first 8h of induction, myeGFP aggregates were rather diffuse and reached less than 60% 
of cells in 8h of induction (Figure 11C).  
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Since different α-synuclein-tag and linker combinations exhibited the same growth 
reduction phenotype and were able to aggregate, it can be concluded that once coupled 
to a tag at the C terminus via a linker sequence, irregardless of the choice of fluorescent 
tag, α-synuclein maintains its cellular toxicity and ability to aggregate. 
 
3.1.5 Tag position and presence of linker are important in 
preserving α-synuclein toxicity and aggregation 
 
In many reports the importance of the tag position in α-synuclein constructs is often 
neglected. Additionally, there is often no description regarding the presence or absence of 
a linker between α-synuclein and the tag. To address the relevance of tag position and 
linker in designing α-synuclein constructs, an eGFP tag was connected N-terminally to α-
synuclein via linker and a myeGFP tag was fused C-terminally without a linker. The nature 
of the tag was previously shown not to interfere with α-synuclein aggregation and ability to 
inhibit yeast growth (Figure 11). Spotting analysis of W303 cells overexpressing WT, 
A30P and A53T α-synucleins coupled N-terminally to the tag or fussed to it without a 
linker revealed no growth inhibition (Figure 12A and B). Furthermore, none of the 
constructs gave rise to aggregates. Either N-terminally tagged via linker or C-terminally 
fused to the tag, WT and A53T α-synucleins remained at the plasma membrane, while 
A30P α-synuclein was distributed throughout the cytoplasm.  
Since α-synuclein was previously able to inhibit growth and to aggregate when C-
terminally tagged via linker (Figure 11), the new lack of growth inhibition and aggregation 
implied that tag position and presence of a linker are mandatory in maintaining α-
synuclein cytotoxicity and aggregation. Additionally, these data offered a direct correlation 
between lack of growth toxicity and lack of α-synuclein aggregation. In further 
experiments, only constructs with C-terminal GFP tags connected to α-synuclein via linker 
were studied. 
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  A                                                                            B 
 
Figure 12. N-terminal linked tags and C-terminal tags fused without a linker prevent α-
synuclein cytotoxicity and aggregation. Spotting analysis and fluorescence microscopy. Cells 
were transformed with a high-copy plasmid carrying WT α-synuclein or mutants (A) N-terminally 
connected to eGFP via SAAAG linker or (B) C-terminally coupled to myeGFP without a linker under 
the control of GAL1 promoter. Cells were pre-grown in non-inducing medium to mid-log phase. 
Tenfold serially-diluted cells were spotted on inducing and non inducing solid medium and 
incubated at 30°C for two days. Cells expressing GFP served as control. Corresponding live-cell 
fluorescent microscopy pictures are shown bellow the spotting assays. Cells were visualized at 8h 
of induction. 
 
3.1.6 Three tandemic copies of WT and two of A53T are 
thresholds for α-synuclein toxicity and aggregation 
 
It was previously reported that in yeast α-synuclein aggregation and toxicity can be 
achieved by expressing the protein from two genomic loci (Outeiro and Lindquist, 2003). A 
main goal in extending the current yeast PD model was to determine the threshold for α-
synuclein cytotoxicity in yeast. Since transformation targeting one genomic locus often 
results in tandemic copy integrations, a quantitative assay was performed to determine 
whether tandem repeats of α-synuclein-KLID-GFP integrated into the ura3 genomic locus 
are sufficient to render α-synuclein toxic and aggregation-prone. This had the additional 
advantage of avoiding genetic interference effects which might arise through second-locus 
integrations. Upon copy-number determination by Southern analysis, strains with one, two 
and three copy integrations of GFP-tagged WT, A30P or A53T α-synuclein were selected 
for analysis.  
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Spotting assays revealed that in the presence of galactose cells expressing one or two 
copies of WT α-synuclein grew uninhibited, while cells expressing three copies were 
unable to grow (Figure 13A). Cells expressing one copy of A53T α-synuclein grew 
uninhibited. Cells expressing two copies of A53T already presented significant growth 
inhibition and cells expressing three copies were unable to grow. The amounts of α-
synuclein in these strains correlated with growth patterns and with gene copy numbers, as 
determined in a western analysis. The protein band corresponding to one copy was lower 
in intensity than the band corresponding to two copies, which was lower in intensity than 
the band corresponding to three copies of the integrated construct. A similar correlation 
was observed at gene level in Southern analysis (Figure 13A). This applied to all α-
synucleins.  
Moreover, α-synuclein copy numbers also correlated with aggregation patterns (Figure 
13B). WT α-synuclein expressed from one genomic copy remained at the plasma 
membrane and at 8h of induction started to develop aggregates in a small percentage of 
cells. Two copies resulted in a low and stable aggregation, while three copies aggregated 
with fast kinetics (Figure 13C). One copy A53T α-synuclein did not present aggregates 
until the 8th hour of induction, similarly to the WT version. Two A53T α-synuclein copies 
aggregated faster than two WT copies and slower than three A53T copies.  
Regarding the A30P variant, neither toxicity nor aggregation had previously been 
described in yeast (Dixon et al., 2005; Outeiro and Lindquist, 2003).  Indeed, when 
expressed from one, two or three copies, A30P α-synuclein was not toxic to yeast growth 
(Figure 13A) and localized throughout the cytoplasm without forming aggregates (Figure 
13B). In comparison, when overexpressed from a high-copy vector, A30P was able to 
aggregate (Figure 10A) and to mildly affect yeast growth (Figures 9 and 13A). In the 
western analysis (Figure 13A), the intensity of the band corresponding to the high-copy 
expressed A30P α-synuclein was considerably higher than the intensities of any of the 
bands corresponding to the integrated α-synuclein copies. This suggested that A30P 
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requires a much higher expression level in comparison to the other α-synuclein variants in 
order to have an effect on yeast growth and to form aggregates.  
 
A                                                                     B 
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Figure 13. Three copies WT α-synuclein and two copies A53T α-synuclein in one genomic 
locus represent thresholds for toxicity and aggregation. Phenotypic analysis of W303 yeast 
strains carrying increasing numbers of WT, A30P or A53T α-synuclein-KLID-GFP integrated into 
the triple-mutated ura3-52 locus. A30P α-synuclein was additionally expressed from a 2µ plasmid 
for comparison. W303 cells carrying integrated GFP in the ura3 locus were used for control 
(denoted C). (A) Spotting analysis (top) reflecting yeast growth impairment with increasing copy 
numbers for WT and A53T and not for A30P α-synuclein. Protein levels (middle) were visualized 6h 
after induction by western analysis using an anti-α-synuclein antibody and, as loading control, an 
anti-eiF2α antibody. Equal amounts of total protein (10 µg/sample) were loaded. α-synuclein gene 
copies were determined by Southern hybridization (bottom) using labeled URA3 as probe. 
Integrated α-synuclein copies correspond to 2.7kb + 4.7kb (1x), 2.7kb + 4.7kb + 6.2kb (2x), 2.7kb + 
4.7kb + higher intensity 6.2kb (3x). Copy numbers were determined with the ImageJ software.     
(B) Copy number-dependent α-synuclein aggregate formation visualized by live-cell fluorescence 
microscopy at indicated time points. White arrows point at the intracellular inclusions.                   
(C) Quantification of α-synuclein aggregate percentages at different time points. The column bars 
represent the average values of three independent experiments. 
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Taken together, these results show that integration of multiple copies of tagged WT or 
A53T α-synuclein into a single yeast genomic locus is sufficient to elicit cytotoxicity and to 
result in aggregates. Three tandemic gene copies of WT α-synuclein were set as 
threshold for cytotoxicity and aggregation, while the threshold for the A53T version was 
lower and closer to two gene copies. In the case of A30P α-synuclein, aggregation and a 
mild yeast growth reduction can be achieved only by strong overexpression. 
 
3.1.7 TAP, co-immunoprecipitation and GFP-Trap reveal no 
interaction partners for α-synuclein in yeast 
 
To obtain more insight into the toxicity mechanisms of PD, next experiments focused on 
finding interaction partners and post-translational modifications of α-synuclein. To this aim, 
α-synuclein was subjected to purification by three alternative methods and analyzed by 
Mass Spectrometry (MS).  
Tandem affinity purification (TAP) was first performed. A TAP tag consisting of a 
calmodulin binding peptide, a tobacco etch virus protease cleavage site and Protein A 
was connected to α-synuclein. As protein A has the property to tightly bind to 
immunoglobulin G (IgG), the entire complex was retrieved using an IgG matrix (Puig et al., 
2001). Two integrative constructs were prepared, one containing C-terminally TAP-tagged 
WT α-synuclein and one carrying N-terminally TAP-tagged WT α-synuclein, both under 
the control of GAL1 promoter. Transformation of the TAP construct targeting the ura3 
locus of W303 yeast resulted in multiple-copy integrations. Strains with two genomic 
copies of TAP-tagged α-synuclein were selected for the experiment. While purification of 
N-terminally TAP-tagged α-synuclein was not successful, purification of the C-terminally 
TAP-tagged α-synuclein resulted in α-synuclein (17 kDa), as shown in a Coomassie 
staining (Figure 14A). MS analysis identified only α-synuclein and no interaction partners. 
An additional query was performed to identify post-translational modifications on the 
protein, yet none was found. The fact that TAP resulted in no α-synuclein interaction 
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partners or post-translational modifications suggested that either there are no α-synuclein 
interaction partners identifiable in yeast or the method was not sensitive enough.  
 
A                                         B                                        C 
 
 
 
 
 
 
 
 
 
 
                      TAP                                     Co- IP                                               GFP-Trap 
Figure 14. Three protein purification methods reveal no interaction partners for α-synuclein 
in yeast. (A) Coomasie staining of protein extracts from W303 cells expressing (1) C-terminally 
TAP-tagged and (2) N-terminally TAP-tagged WT α-synuclein from two genomic copies. Cells were 
induced for 24h and subjected to TAP purification. (B) Coomasie staining on co-
immunoprecipitated (co-IP) α-synuclein. Overnight-grown cells were induced for 24h to express WT 
α-synuclein (1) from a high-copy vector and (2) from two genomic copies then subjected to Co-IP. 
(C) Coomassie staining of GFP-Trap-ed α-synuclein. W303 cells expressed (1) WT, (2) A30P and 
(3) A53T GFP-tagged α-synuclein from a 2µ plasmid and (4) GFP-tagged WT α-synuclein from two 
genomic copies for 24h. Cells expressing GFP alone served as control.  
 
 
An alternative method employed to purify α-synuclein while pulling it down together with 
interaction partners was co-immunoprecipitation (Co-IP). Co-IP is based on precipitating 
the protein of interest as part of an interaction complex using an antibody that specifically 
binds to the protein. Co-IP was performed both with low-copy expressed and with 
overexpressed WT α-synuclein. For purification, the complex was pulled out on an IgG 
matrix (Phizicky and Fields, 1995). The proteins were pulled down successfully (Figure 
14B). MS data identified only α-synuclein and contaminating proteins such as ribosomal 
factors. Additionally, no post-translational modifications were detected on α-synuclein.  
A last attempt to find interaction partners or post-translational modifications of α-synuclein 
was GFP-Trap. The principle of GFP-Trap relies on trapping the GFP-tagged protein of 
interest on IgG beads coated with anti-GFP antibodies (chromotek, Martinsried, 
Germany). The experiment was performed with overexpressed WT, A30P and A53T α-
synuclein as well as with low copy-expressed WT α-synuclein. A Coomassie staining of 
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the purified GFP-tagged α-synucleins showed that the purification was successful (Figure 
14C). The protein bands were subjected to MS, which identified ony α-synuclein and GFP. 
No interaction partners and no post-translational modifications were found.   
Aiming to identify post-translational modifications besides interaction partners of α-
synuclein and assuming that the sensitivity of MS might not suffice to detect them, a 
western hybridization was performed on the purified tagged and untagged α-synucleins. 
The membrane was probed with antibodies against ubiquitin, Smt3 and 3-nitro-tyrosine, 
yet no signals were detected.  
Several purification methods tested and optimized to find α-synuclein interaction partners 
resulted in the identification of either α-synuclein or α-synuclein-GFP alone. This 
suggested that in yeast α-synuclein and α-synuclein-GFP do not interact stoichiometrically 
with other proteins except themselves.  
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3.2 Degradation pathways involved in α-synuclein aggregate 
clearance  
 
3.2.1 Yeast cells can recover from transient α-synuclein 
expression 
 
Having established the criteria for a functional yeast PD model, the next aim was to 
investigate whether and how yeast cells cope with α-synuclein aggregation. Subsequent 
experiments questioned whether yeast can recover from α-synuclein-induced toxicity by 
clearing α-synuclein aggregates. This idea was supported by the observation that yeast 
cells overexpressing A30P α-synuclein were only mildly affected in growth and were able 
to reduce aggregation from 35% at 8h of induction to 12% at 24h (Figure 10B), suggesting 
an intrinsic cellular clearing mechanism to counteract aggregation. 
Recovery from α-synuclein toxicity was investigated by promoter shut-off experiments. 
W303 yeast cells were induced for 8h in galactose to express WT α-synuclein or the A30P 
and A53T variants in both low and high copies. The GAL1 promoter was switched off by 
spotting cells on solid medium supplemented with glucose, as glucose promptly represses 
GAL1 (Lamphier and Ptashne, 1992). In parallel, for control, cells were spotted on 
galactose solid medium (Figure 15A). Cells plated on glucose grew uninhibited (Figure 
15B), suggesting that they were able to recover from transient α-synuclein exposure. This 
was observed for all α-synuclein versions. Cells plated on galactose for control presented 
a growth deficit, as established in previous spotting analyses (Figures 9 and 13).  
To gain more insight into the rapidity of recovery, the ability of cells to form colonies after 
promoter shut-off was quantified. The yeast strain employed for this experiment was 
W303 harboring three genomic copies of A53T α-synuclein (3xA53T), as this strain had 
the most toxic phenotype in the gene dosage analysis (Figure 13). 
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A                                                                   B 
 
Figure 15. Yeast cells can recover from transient α-synuclein expression. (A) Experimental 
scheme for promoter shut-off. Cells were induced for 8h in galactose to express α-synuclein either 
from genomic copies or from high-copy plasmids. The GAL1 promoter was shut off by plating the 
cells on glucose. In parallel, as control, the promoter was kept on by plating the cells on galactose. 
(B) Spotting analysis. Yeast cells were induced in galactose medium for 8h to express GFP-tagged 
WT, A30P or A53T α-synuclein from genomically-integrated copies or from high-copy plasmids 
then spotted on glucose and galactose. Aggregation percentages at 8h of induction are shown on 
the right.  
 
Yeast cells were induced in galactose for 8h to express either 3xA53T α-synuclein or GFP 
as control. In parallel, the cells were cultured in non-inducing media (raffinose). After 
being plated on glucose, cells grew normally despite having been subjected to α-synuclein 
stress for 8h, which validated the recovery ability (Figure 16A). Cells plated on galactose 
continued to express A53T α-synuclein and presented inhibited growth. Cells pre-
incubated in galactose had a more pronounced growth inhibition than cells pre-incubated 
in raffinose, which corroborated the increased toxicity of α-synuclein with longer 
expression time. Control cells expressing GFP were able to grow normally both on 
glucose and galactose, underlining the non-toxic effect of GFP on yeast growth in 
comparison to α-synuclein.  
The same cells harboring three genomic copies of A53T α-synuclein used in the spotting 
analysis (Figure 16A) were investigated for their ability to form colonies once the 8h-
expression of α-synuclein was interrupted. Uninduced cells served as control. After 8h 
pre-incubation, cells were plated on solid YPD medium containing glucose and observed 
by light microscopy. Colony formation was quantified by counting developing colonies and 
reporting them to the total number of cell groups. In the first ten hours after promoter shut-
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off, cells which had expressed A53T α-synuclein were distinctly delayed with cell division 
and had a significantly slower colony formation kinetic compared to uninduced cells 
(Figure 16B). 24h after promoter shut-off, α-synuclein-exposed cells were forming 
colonies at a rate comparable to the control. The data suggested that yeast cells need 24h 
for recovery from 8h-induced α-synuclein toxicity.  
 
                           A  
                                                                             
 
 
 
                           B                                              
 
 
 
 
 
 
Figure 16. Yeast cells need 24h to grow normally after transient α-synuclein expression.   
(A) Spotting analysis. W303 cells were induced for 8h in galactose to express GFP-tagged A53T α-
synuclein from three genomic copies (3xA53T) then spotted on glucose and galactose. Cells 
expressing GFP served as control. For comparison, the same strains were grown in raffinose and 
spotted. (B) Quantification of colony formation. The graph shows the percentages of cells forming 
colonies after promoter shut-off. The column bars represent the mean values of 3 independent 
experiments.  
 
3.2.2 Yeast cells can clear cytoplasmic α-synuclein inclusions 
Assuming that recovery from growth toxicity may be related to α-synuclein aggregate 
clearance, the effect of promoter shut-off on α-synuclein aggregates was next 
investigated. To this aim, W303 yeast cells harboring three genomically-integrated copies 
of WT α-synuclein-KLID-GFP were induced in galactose medium for 2h then shifted to 
glucose for promoter shut-off. Fluorescence microscopy and aggregation quantification at 
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several time points after promoter shut-off revealed a drastic reduction of α-synuclein 
aggregates in time (Figure 17A and B), suggesting that yeast is able to clear α-synuclein 
aggregates once the induction of α-synuclein is stopped. An increase in the galactose pre-
incubation time to 4h resulted in a slower aggregate clearance kinetic than the one 
corresponding to 2h pre-incubation (Figure 17B). Thus, the longer the induction of α-
synuclein, the more difficult it is for cells to clear aggregates. The data showed that yeast 
not only recovers from α-synuclein exposure but also clears α-synuclein aggregates in a 
dosage-dependent manner, as soon as the further α-synuclein supply is interrupted.  
 
    A                                             
 
 
 
 
Figure 17. Yeast cells can clear α-synuclein aggregates upon promoter shut-off. (A) Live-cell 
fluorescence microscopy of W303 cells harboring three copies of genomically-integrated wild type 
α-synuclein-KLID-GFP (3xWT) at 2h of galactose (left) and after 2h of glucose (right).                  
(B) Fold decrease of α-synuclein aggregation after promoter shut-off at the indicated time points. 
Pre-incubation in galactose was done for two or four hours. Aggregation percentages were 
calculated from three independent experiments.  
 
3.2.3 Vacuolar proteases are required for α-synuclein aggregate 
clearance 
 
Promoter shut-off after transient α-synuclein induction resulted in aggregate clearance, 
which raised the question of α-synuclein degradation. In the past, α-synuclein was 
proposed to be degraded by both autophagy and the proteasome (Webb et al., 2003). The 
importance of these two degradation systems was investigated here by inhibiting the 
systems and analyzing subsequent impact on α-synuclein aggregate clearance. Inhibition 
was achieved through a chemical and a genetic approach. 
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Drug treatments in yeast have always posed the challenge of cell wall penetration (Lee 
and Goldberg, 1996). While drugs can easily penetrate mammalian membranes, in yeast 
they would encounter the resistance of a chitin cell wall. A practical solution for drug 
treatments in yeast is offered by the Δerg6 (Δise1) mutant defective in the biosynthesis of 
ergosterol, the main membrane sterol of yeast. This modification leads to biochemical and 
structural alterations in the cell wall, increasing its permeability (Graham et al., 1993).  
In this study, drug inhibition experiments were performed with the Δerg6 mutant. The drug 
MG132 was used to inhibit proteasomal activity and phenylmethylsulfonyl fluoride (PMSF) 
was used to inhibit the activity of vacuolar proteases (Lee and Goldberg, 1998). Promoter 
shut-off experiments were performed simultaneously with drug treatments. Δerg6 cells 
were induced for 4h to overexpress WT α-synuclein from high-copy plasmids before being 
shifted to glucose media supplemented with drugs or their corresponding vehicles.  
Treatment of yeast cells with MG132 was previously reported to block cell cycle 
progression, increase accumulation of polyubiquitinated proteins, inhibit the proteasome 
and decrease transcription of several genes (Collins et al., 2010). As proof that MG132 
actually affected cells, a western hybridization revealed a three-fold increase in the 
amount of ubiquitinated proteins in treated cells compared to untreated cells (Figure 18).   
                                                     
                     A                                                       B 
  
 
 
 
 
Figure 18. MG132 increases the amount of ubiquitinated proteins three-fold. (A) Western blot. 
Δerg6 cells were induced for 4h in galactose to express GFP-tagged WT α-synuclein from a 2µ 
plasmid then shifted to glucose with 50 µM MG132. For control, cells were transferred to glucose 
without the drug. 4h after the transfer, cells were broken and the protein extracts were subjected to 
western analysis. A mouse anti-ubiquitin antibody was used to assess the total levels of 
ubiquitinated proteins. (B) Quantification of ubiquitin signals. Pixel volumes corresponding to total 
ubiquitinated protein were compared in MG132-treated and control samples. The factor difference 
of 2,53 was estimated at 3-fold increase in the amount of ubiquitinated proteins in the MG132 
sample.  
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Quantification of aggregate percentages after α-synuclein promoter shut-off showed that 
MG132-treated cells were able to clear aggregates in a similar manner as cells treated 
with the vehicle (DMSO) and as untreated cells (Figure 19). Since the effect of MG132 on 
aggregate clearance was not significant, it could be concluded that proteasome inhibition 
does not prevent cells from clearing α-synuclein aggregates, therefore, this degradation 
system has a minor contribution to α-synuclein aggregate clearance.  
 
 
 
 
 
 
 
 
 
 
Figure 19. Cells treated with the vacuolar serine protease inhibitor PMSF but not with the 
proteasome inhibitor MG132 have lost the potential to clear α-synuclein aggregates upon 
promoter shut-off. Δerg6 cells were induced for 4h in galactose to overexpress GFP-tagged WT 
α-synuclein then transferred to glucose. The glucose media were supplemented with 50 µM 
MG132 or the respective vehicle (DMSO) and with 1 mM PMSF or the respective vehicle (EtOH). 
Additionaly, cells were transferred to glucose but not treated. Fold decrease in aggregation 
percentages was calculated as a result of three independent experiments. 
 
Phenylmethylsulfonyl fluoride (PMSF) inhibits the activity of many vacuolar serine 
proteases (Jones, 1991) without affecting proteasome function (Dubiel et al., 1992). 
PMSF treatment was done under similar conditions as MG132 treatment. Quantification of 
α-synuclein aggregation after promoter shut-off and PMSF treatment revealed that cells 
were no longer able to clear the aggregates (Figure 19). Control cells treated with the 
PMSF vehicle (EtOH) and untreated cells cleared aggregates, suggesting that the 
observed inhibitory effect on aggregate clearance is due to PMSF. The data indicated that 
PMSF had blocked pathways which play an important role in α-synuclein aggregate 
 T, Δerg6 
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clearance. Since PMSF is a serine protease inhibitor, it is likely that serine proteases are 
required for aggregate clearance. 
To further verify the effects of MG132 and PMSF on α-synuclein aggregate clearance 
drug treatments were also applied to Δerg6 cells induced in galactose to express WT α-
synuclein. The medium was supplemented with MG132, PMSF or both drugs. For control, 
the galactose medium was either left drug-free or was supplemented with the vehicles of 
the drugs. Aggregation quantification in the early hours of induction showed that α-
synuclein aggregated in a similar manner in MG132-treated cells, in DMSO-treated cells 
and in untreated cells (Figure 20), meaning that MG132 had an insignificant effect on α-
synuclein aggregation. α-synuclein aggregation percentages of cells treated with PMSF 
were higher than those of untreated cells and than those of cells incubated with the EtOH 
vehicle (Figure 20). This suggested that PMSF treatment not only prevents yeast cells 
from clearing α-synuclein aggregates, but also enhances α-synuclein aggregation.  
 
 
 
 
 
 
 
 Figure 20. Enhanced α-synuclein aggregation upon PMSF-mediated inhibition of vacuolar 
proteases. Aggregation quantification in Δerg6 cells expressing GFP-tagged WT α-synuclein from 
a high-copy plasmid at indicated time points. Galactose media were supplemented with 50 µM 
MG132 or the respective vehicle (DMSO), with 1 mM PMSF or the respective vehicle (EtOH) and 
with 50 µM MG132 and 1 mM PMSF (drugs) or the corresponding solving agents, DMSO and 
EtOH (vehicles). Additionaly, cells were induced in galactose without being exposed to drugs. 
Quantifications were done as a result of three independent experiments.  
 
Since no significant differences were recorded between the aggregation percentages of 
cells treated with PMSF and of cells treated with both drugs and since the effect of MG132 
treatment was not substantial on its own, the effect observed with both drugs was due to 
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PMSF. This additionally implied that combined inhibition of the proteasome and of 
vacuolar pathways does not enhance aggregation more than inhibition of vacuolar 
pathways does. Therefore, vacuolar degradation plays a significantly more important 
function in α-synuclein aggregate clearance than the ubiquitin-proteasome system. 
 
3.2.4 Higher contribution of autophagy and the vacuole than of 
the proteasome in α-synuclein aggregate clearance 
 
To validate the lack of proteasome involvement in α-synuclein aggregate clearance, a 
genetical approach was employed. The temperature-sensitive cim3-1 mutant was 
considered. This mutant is defective in one of the AAA+ ATPases of the 19S proteasome 
regulatory subunit which unfolds target proteins (Ghislain et al., 1993). Proteasomal 
degradation is thereby abolished in this mutant. Wild type W303 and cim3-1 cells were 
transformed with high copy plasmids carrying WT α-synuclein under the control of GAL1 
promoter. Compared to the parental strain, 4h incubation of cim3-1 cells in galactose 
resulted in lower α-synuclein aggregation percentages. Upon promoter shut-off, the 
mutant was able to clear α-synuclein aggregates even with a faster kinetic than the wild 
type W303 parental strain (Figure 21), confirming a minor contribution of the proteasome 
to α-synuclein aggregate clearance. 
Since PMSF was reported to affect autophagic body formation (Takeshige et al., 1992) 
and PMSF-treated cells were unable to clear α-synuclein aggregates (Figure 19), the next 
question addressed was whether aggregate clearance could occur via autophagic 
pathways. Promoter shut-off studies were performed with a Δatg1 mutant unable to 
perform autophagy. ATG1 stands for autophagy-specific gene 1 and the Atg1 protein is a 
serine/threonine kinase essential for autophagy induction (Matsuura et al., 1997). WT α-
synuclein was expressed in the Δatg1 mutant from a high-copy plasmid. Promoter shut-off 
analysis indicated that Δatg1 cells did not clear aggregates for the first 120 min, in 
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contrast to the parental strain which did (Figure 21). This suggested that autophagy 
contributes to aggregate clearance.  
Previous cell culture studies reported that once the proteasome is impaired and cannot 
clear aggregates efficiently, autophagy becomes the main degradation pathway (Rideout 
et al., 2004). To test whether the specific inhibtion of both these systems would prevent 
clearance, the double mutant cim3-1Δatg1 was considered. Promoter shut-off analysis 
showed that cim3-1Δatg1 cells cleared aggregates in a similar manner as Δatg1 cells 
(Figure 21). This validated the minor contribution of the proteasome to α-synuclein 
aggregate clearance and favored the previous conclusion that vacuolar pathways have a 
higher contribution to the process. The fact that the double inhibition did not completely 
prevent cells from clearing α-synuclein aggregates suggested that there could be 
additional pathways involved in clearance.  
 
 
 
 
 
 
 
 
 
Figure 21. Involvement of autophagy and vacuolar pathways in α-synuclein aggregate 
clearance upon promoter shut-off. Degradation-related mutants cim3-1, Δatg1, cim3-1Δatg1 and 
Δpep4 together with W303 and BY4741 wiltd-type strains were preincubated in galactose to 
express GFP-tagged α-synuclein from a high-copy vector. After four hours, the cells were shifted to 
glucose. Aggregation percentages after promoter shut-off were used to calculate the fold decrease 
in aggregation. Data was quantified from three independent experiments.  
 
 
A Δpep4 mutant was included in promoter shut-off experiments to obtain more insight into 
the extent to which vacuolar degradation is involved in α-synuclein aggregate clearance. 
Since the mutant had BY4741 as genetic background, an additional control consisting in 
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the BY4741 parental strain was included in the analysis. The PEP4 gene of S. cerevisiae 
encodes for the vacuolar protease proteinase A, which initiates the maturation and 
activation of several vacuolar hydrolases, such as carboxypeptidase Y, proteinase B and 
aminopeptidase I (Parr et al., 2007; Woolford et al., 1986). Δpep4 cells were able to clear 
α-synuclein aggregates less efficiently than control cells (Figure 21), presenting an 
intermediate clearance response. This supported the fact that vacuolar proteases are 
involved in α-synuclein aggregate clearance. Since Δpep4 cells were able to clear most of 
the aggregates by the fourth hour of promoter shut-off, it was concluded that there are 
more proteases involved in the process than the ones controlled by proteinase A. 
Taken together, the data obtained through the genetic approach corroborated the results 
obtained with chemical treatments and confirmed the importance of autophagic and 
vacuolar pathways in α-synuclein aggregate clearance in comparison to a minor function 
of proteasomal degradation. 
 
3.2.5 Lack of Ypt7 Rab GTPase affects α-synuclein localization 
The importance of vacuolar pathways in α-synuclein aggregate clearance raised the 
assumption that α-synuclein is targeted to the vacuole for degradation. To follow α-
synuclein localization, fluorescence microscopy was performed with a Δypt7 mutant. Ypt7 
is a GTP-binding protein belonging to the Rab GTPase family which consists of small 
proteins involved in multiple stages of membrane traffiking (Grosshans et al., 2006; 
Wichmann et al., 1992). Ypt7 is required for the homotypic fusion event in vacuole 
inheritance, for endosome-endosome fusion and for endosome-to-vacuole fusion 
(Schimmoller and Riezman, 1993). Δypt7 mutants are characterized by highly fragmented 
vacuoles and differential defects of vacuolar protein transport and maturation (Wichmann 
et al., 1992). 
Overexpression of α-synuclein in Δypt7 resulted in a re-localization phenotype, where α-
synuclein accumulated in the cytosol in a ring-like granular pattern (Figure 22A right) 
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instead of forming the typical aggregates visible in the wild type background (Figure 22A 
left). The percentage of cells displaying this re-localization phenotype increased with time 
(Figure 22B). No aggregates developed throughout an 8h time-course. The ring-like 
arrangement developed gradually and was already very prominent by the first hour of 
induction (Figure 22C). The inability of α-synuclein to form aggregates in the Δypt7 mutant 
suggested that Ypt7 promotes α-synuclein aggregate maintainance. 
Ypt7-deficient cells have numerous small vacuoles (Wichmann et al., 1992). To determine 
whether α-synuclein co-localizes with them, stainings with the lypophilic dye FM4-64 were 
performed. FM4-64 binds lipid membranes and is internalized via endocytosis, thereby 
staining vacuolar as well as vesicular mebranes (Vida and Emr, 1995).  
 
              A                                                     B 
 
 
 
C 
 
Figure 22. Lack of Ypt7 affects the localization of α-synuclein. (A) Live-cell fluorescence 
microscopy. Δypt7 mutant and the parent strain BY4741 transformed with a high-copy vector 
carrying WT α-synuclein-KLID-GFP (WT) were induced in galactose for 4h. (B) Quantification of 
Δypt7 cells with α-synuclein accumulations at 2, 4 and 8h of induction. (C) Live-cell fluorescence 
microscopy depicting WT α-synuclein accumulation in the Δypt7 mutant in the first 60 min of 
induction. 
 
In the BY4741 wild type control as well as in the Δypt7 mutant the red fluorescence signal 
of FM4-64 overlapped with the green fluorescence signal of WT α-synuclein-GFP as a 
sign of collocalization. In BY4741, α-synuclein co-localized with the vacuolar membrane 
and with endocytic vesicles (Figure 23A), while in Δypt7, it co-localized with the numerous 
vacuoles, characteristic of the mutant (Figure 23B). In wild type cells α-synuclein binding 
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to the vacuolar membrane was observed only in the first two hours of induction, whereas 
in Δypt7 cells the localization persisted over time. α-synuclein co-localization with Δypt7 
vacuoles was visible for all α-synuclein versions.  
 
A                                                                               B 
 
 
 
 
 
 
 
 
Figure 23. α-synuclein co-localizes with endocytic vesicles and vacuoles. FM4-64 stainings in 
(A) BY4741 cells expressing WT α-synuclein and (B) Δypt7 cells expressing GFP-tagged WT, 
A30P, A53T and TP α-synuclein. After two hours of α-synuclein induction, cells were incubated 
with 1 nM FM4-64 for 20 min, washed and visualized by fluorescence microscopy. Red, green and 
merged fluorescence images are shown. 
 
To assess whether lack of Ypt7 affects α-synuclein toxicity to yeast growth, the growth of 
Δypt7 cells was compared to the growth of BY4741 cells upon α-synuclein overexpression 
(Figure 24 A and B).  
 
  A             B 
 
 
Figure 24. Lack of Ypt7 does not affect α-synuclein toxicity. Spotting analysis of (A) parent 
strain BY4741 and (B) Δypt7 mutant transformed with a high-copy vector carrying GFP-tagged WT, 
A30P, A53T or TP α-synuclein controlled by the GAL1 promoter. Cells expressing GFP served as 
control. The plates were incubated at 30°C for 2 days then photographed. 
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The toxicity of α-synuclein on cell growth was the same in the Δypt7 mutant as in the 
parent strain. This implied that lack of Ypt7 does not render A30P or TP α-synuclein toxic 
and neither does it alter the toxicity of the WT and A53T versions.  
Taken together, these results show that lack of Ypt7 leads to an accumulation of α-
synuclein in the cytosol, which does not affect its toxic effect on yeast growth. Futhermore, 
α-synuclein co-localization with the vacuolar membrane and with endocytic vesicles in wild 
type cells as well as with fragmented vacuoles in Δypt7 cells hint at an interaction 
between α-synuclein and the endocytic pathway. Thus, α-synuclein could presumably be 
targeted to the vacuole for degradation. 
 
3.2.6 The autophagy-inducing drug rapamycin promotes α-
synuclein aggregate clearance 
 
Yeast autophagy is controlled by TOR kinases (Noda et al., 2002). A small molecule 
which inhibits TOR is rapamycin, a macrolide antibiotic with anti-fungal and 
immunosuppressive properties (Wullschleger et al., 2006). Rapamycin has been used in 
many organisms to upregulate autophagy via TOR inhibition, including yeast (Kamada et 
al., 2004). 
In this study, rapamycin was applied to yeast expressing α-synuclein with the aim of 
obtaining a deeper insight into the contribution of autophagy to α-synuclein aggregate 
clearance. First, W303 cells expressing GFP-tagged α-synuclein from two genomic loci 
(HiTox strain, Outeiro and Lindquist, 2003) were induced to express α-synuclein for 3h 
then incubated with rapamycin. 6h of α-synuclein induction with 3h of rapamycin treatment 
resulted in a decreased α-synuclein aggregation percentage, with no major differences 
among several drug concentrations tested (Figure 25A and C).  
When cells were pre-incubated with rapamycin for one hour and washed before α-
synuclein induction, the effects were dramatic. In the first hours of α-synuclein induction, 
cells could not develop aggregates and only plasma membrane localization of α-synuclein 
Results 
 
 
 
- 63 - 
 
was observed (Figure 25B). 6h of induction resulted in low aggregation percentages for all 
rapamycin concentrations tested. Moreover, the number of aggregates per cell was 
drastically reduced (Figure 25B and C). These data suggested that rapamycin pre-
treatment was more effective than treatment after α-synuclein induction.  
 
           
 
 
 
 
 
          
               
 
 
 
 
 
 
 
Figure 25. Rapamycin decreases α-synuclein aggregation. (A) Rapamycin treatment. W303 
cells were induced in galactose to express GFP-tagged α-synuclein from two genomic loci (HiTox, 
Outeiro and Lindquist, 2003). At 3h of induction, when the aggregation percentage was 69% ± 8%, 
the galactose medium was supplemented with either 20, 50 or 100 nM rapamycin. For control, cells 
were left untreated. Live-cell fluorescence microscopy was performed after 6h of galactose 
induction and 3h of rapamycin treatment respectively. (B) Rapamycin pre-treatment. The three 
rapamycin concentrations were also applied to cells 1h before α-synuclein induction. After 1h of 
pre-treatment, cells were washed and shifted to galactose. 6h later, live-cell fluorescence 
microscopy was performed. No pre-treatment was applied to control cells. (C) Quantification of α-
synuclein aggregation in cells treated and pre-treated with rapamycin. The column bars represent 
the mean values of three independent experiments.  
 
The fact that α-synuclein aggregation percentages were reduced in both scenarios of 
rapamycin treatment suggested that TOR signaling is involved in α-synuclein aggregate 
clearance. Since TOR controls autophagy induction, the data further imply that autophagic 
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pathways are involved in α-synuclein aggregate clearance. Nevertheless, it should be 
taken into account that TOR inhibition by rapamycin affects not only autophagy but 
several other metabolic pathways (De Virgilio and Loewith, 2006).  
As α-synuclein concentration proved to be an important factor in defining cytotoxicity and 
aggregate formation (Figure 13), the next step was to investigate whether rapamycin-
induced aggregate clearance depends on α-synuclein dosage. Rapamycin effects on cells 
challenged with different α-synuclein concentrations were assessed in three scenarios of 
treatment. The drug was applied to cells expressing α-synuclein from two tandemic copies 
integrated in the genome or from a high-copy vector, before, at the same time, and after 
induction. Aggregation levels were monitored throughout time. 
When α-synuclein was expressed from two genomic copies, rapamycin pre-treatment and 
treatment at the same time with α-synuclein induction prevented α-synuclein aggregate 
formation. Treatment started three hours after α-synuclein induction was less efficient than 
pre-treatment. However, it still reduced aggregation percentages with more than 50% 
compared to the untreated sample at the same time point. Aggregate size and number of 
aggregates per cell were smaller in rapamycin-exposed cells than in control cells (Figure 
26A).  
When α-synuclein was expressed from high-copy plasmids, rapamycin pre-treatment 
prevented aggregate formation in the first few hours of induction (Figure 26B). Cells were 
able to develop aggregates with time, reaching 49% aggregation at 8h of induction. This 
represented a substantial difference in comparison with untreated cells which displayed 
81% aggregation at the same time point. Rapamycin treatment simultaneous with α-
synuclein induction decreased aggregation with only 10% (Figure 26B) compared to 100% 
in the same treatment scenatio with low-copy α-synuclein expression (Figure 26A). 
Rapamycin treatment after α-synuclein induction from a high-copy vector resulted in 20% 
clearance and was less efficient than for low-copy expressed α-synuclein.  
The decreased rapamycin clearance efficiency with increased α-synuclein concentration 
suggested that rapamycin clears α-synuclein aggregates in a dosage-dependent manner. 
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Figure 26. Rapamycin efficiency decreases with increased α-synuclein concentration. Live-
cell fluorescence microscopy. W303 cells were induced to express WT α-synuclein (A) from two 
genomically-integrated copies (α-synuclein-AAAG-myeGFP) and (B) from a high-copy plasmid (α-
synuclein-KLID-GFP). For rapamycin pre-treatment, cells were incubated in raffinose medium 
supplemented with 100 nM rapamycin for 1h and washed prior to transfer to galactose. For 
treatment+induction, cells pre-grown in raffinose were shifted to galactose supplemented with 100 
nM rapamycin. For treatment after induction, at the 3h time point of α-synuclein induction 
rapamycin was added to the galactose medium at a final concentration of 100 nM. Untreated cells 
served as control. At 3h of induction the aggregation percentage of WT α-synuclein-AAAG-
myeGFP expressed from two genomic copies was 29% ± 8%. Time points after α-synuclein 
induction and aggregation percentages are indicated.  
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To determine whether rapamycin discriminates between the aggregates of different α-
synuclein variants, the drug was applied to cells overexpressing WT, A30P and A53T α-
synuclein in different treatment scenarios (Figure 27).  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Rapamycin pre-treatment is impartial to α-synuclein species. Aggregation 
quantification. W303 cells expressed GFP-tagged (A) WT, (B) A30P and (C) A53T α-synuclein from 
a high-copy plasmid. For rapamycin pre-treatment, cells were incubated in raffinose supplemented 
with 100nM rapamycin for 1h and washed prior to transfer to galactose. For treatment+induction, 
cells pre-grown in raffinose were shifted to galactose supplemented with 100 nM rapamycin. For 
treatment after induction, 100 nM rapamycin were added to the medium after three hours of α-
synuclein induction. Untreated cells served as control. α-synuclein aggregation percentages at 
different time points of α-synuclein induction are presented as column bars.   
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For all three α-synuclein variants, rapamycin pre-treatment was the most efficient 
treatment scenario, delaying formation of aggregates and considerably reducing their 
percentages later on. Rapamycin treatment after α-synuclein induction and treatment at 
the same time with induction reduced WT and A53T α-synuclein aggregation by 10-20% 
(Figure 27A and C) and seemed to increase the aggregation of A30P α-synuclein (Figure 
27B), proving to be less effective than pre-treatment.  
Since all α-synucleins responded similarly to rapamycin pre-treatment and WT and A53T 
α-synucleins showed comparable responses to treatments, it was concluded that 
rapamycin-induced α-synuclein aggregate clearance in yeast is not variant-specific. 
 
3.2.7 WT and A53T α-synuclein delay induction of autophagy  
The final aim of this study was to investigate the interplay between α-synuclein and 
autophagy in yeast. Promoter shut-off analysis and rapamycin studies demonstrated the 
involvement of autophagy in α-synuclein aggregate clearance in yeast. Conversely, to 
assess the extent to which α-synuclein influences autophagy, a macroautophagy-
monitoring assay (Cheong et al., 2005) was employed. The assay is based on the fact 
that once autophagy is induced, the ubiquitin-like protein Atg8 coupled N-terminally to 
GFP is delivered to the vacuole via the Cvt pathway. Autophagy is inducible in yeast by 
nitrogen starvation which can be achieved by incubation in a nitrogen-deficient medium 
such as SD(-N) (Takeshige et al., 1992). Upon autophagy induction, GFP-Atg8 is 
delivered to the vacuole. Atg8 is degraded inside the vacuole and GFP is released in the 
cytoplasm. This can be visualized on a western membrane as the appearance of an 
additional protein band corresponding to GFP. The signal of processed GFP is quantified 
as percentage from the sum of processed and unprocessed GFP signals. This defines the 
percentage of autophagy processing in a sample (Cheong et al., 2005).  
W303 wild type yeast was co-transformed with vectors harboring untagged α-synuclein 
and GFP-Atg8. The expression of GFP-Atg8 did not affect the typical yeast growth 
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reduction induced by α-synuclein (Figure 28A). In turn, α-synuclein overexpression did not 
interfere with GFP processing. Relocalization of the GFP signal visualized before and 
after transferring cells to SD(-N) mdium confirmed that autophagy was successfully 
induced (Figure 28B). 
 
  A                                                                               B 
 
Figure 28. GFP-Atg8 does not interfere with α-synuclein toxicity and α-synuclein does not 
affect GFP-Atg8 processing. (A) Spotting analysis of wild type W303 yeast cells co-transformed 
with high-copy plasmids carrying untagged α-synuclein or mutants under the control of GAL1 
promoter and GFP-Atg8 under the control of the copper-inducible promoter CUP1. (B) Live-cell 
fluorescence microscopy of W303 cells induced for 2h in galactose supplemented with 50 µM 
CuSO4 to express untagged WT α-synuclein and GFP-Atg8 (left). Cells were shifted to nitrogen 
starvation medium SD(-N) and observed by fluorescence microscopy four hours later (right).  
 
First, the autophagy ratios of cells growing under normal conditions of α-synuclein 
induction were analyzed. The western membrane revealed three GFP-related protein 
bands. The top one correspsonded to GFP-Atg8 (~40 kDa) and the bottom one to GFP 
(~27 kDa). The middle one presumably corresponded to GFP-Atg8-PE, where Atg8-PE is 
the lipidated form of Atg8. Atg8-PE usually migrates faster than Atg8 (Huang et al., 2000; 
Kirisako et al., 2000). For calculating the GFP processing percent, the GFP-Atg8 and the 
GFP bands were considered. The western membrane was additionally probed with an 
anti-α-synuclein antibody to ensure the expression of α-synuclein. 
The data showed that autophagy percents varied among cells expressing different α-
synuclein variants (Figure 29A). In the first four hours of α-synuclein induction, differences 
between autophagy ratios of cells expressing WT, A53T and TP α-synuclein and control 
were minor. At 2h of induction, the autophagy ratio of cells expressing A30P was 
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substantially higher than that of control, suggesting that A30P can up-regulate autophagy. 
By the 8th hour of induction, this ratio became comparable to that of control, meaning that 
the effect was only transient. At 4h of induction the autophagy ratio of cells expressing 
A53T was smaller than that of control cells. At 8h of induction this ratio became half of the 
control autophagy ratio, suggesting a progressive inhibitory effect of A53T on autophagy 
(Figure 29A).  
 
           A 
 
 
 
 
 
 
B 
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Figure 29. α-synuclein perturbs autophagy. (A) Quantification of autophagy in cells expressing 
untagged α-synuclein or variants at the indicated time points during eight hours of induction. Prior 
to α-synuclein induction cells were incubated for 2h in raffinose medium supplemented with 50 µM 
CuSO4 to express GFP-Atg8 then washed. The column bars represent the average of four 
independent experiments. Cells which expressed GFP-Atg8 but not α-synuclein served as control. 
(B) Corresponding western blots at 2, 4 and 8h of α-synuclein induction. Membranes were probed 
with anti-GFP and anti α-synuclein antibodies.  
 
Autophagy-monitoring assays were employed not only to analyze the influence of α-
synuclein on autophagy but also to determine whether α-synuclein interferes with the 
induction of this process. Cells expressing α-synuclein for 4h were shifted to autophagy-
inducing medium, SD(-N). To maintain α-synuclein expression during nitrogen starvation, 
the medium was prepared with galactose as carbon source. Quantifications of autophagy 
processing showed that A30P and TP α-synucleins did not influence autophagy 
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throughout time, as the autophagy ratios in cells expressing these variants were 
comparable to those of control (Figure 30A). In contrast, the autophagy ratios of cells 
expressing WT and A53T α-synuclein were considerably lower than those of control. 
These differences were less pronounced at 4h that at 2h of starvation, suggesting that WT 
and A53T α-synucleins do not inhibit but delay autophagy induction.    
 
 A 
 
 
    
 
 
            B                                    
                                                    2h                                      4h       
 
 
                         
 
 
Figure 30. WT and A53T α-synucleins delay autophagy induction. (A) Quantification of 
autophagy under starvation conditions. Cells were induced for 4h in galactose to produce α-
synuclein then shifted to nitrogen starvation medium SD(-N) medium further supplemented with 
galactose. Prior to α-synuclein induction cells were incubated for 2h in raffinose medium 
supplemented with 50 µM CuSO4 to express GFP-Atg8 then washed. Probes were taken at 2 and 
4h after the shift. W303 cells which expressed GFP-Atg8 but not α-synuclein served as control. The 
column bars represent the average of four independent experiments. (B) Corresponding western 
blots at 2 and 4h of starvation. Membranes were probed with anti-GFP and anti α-synuclein 
antibodies.  
 
Cell culture models have proposed that besides autophagy, the 26S proteasome is 
involved in α-synuclein clearance (Webb et al., 2003; Rott et al., 2008). To determine 
whether proteasome inhibition would enhance the previously observed inhibitory effects of 
α-synuclein on autophagy, autophagy-monitoring assays were performed with the 
temperature-sensitive proteasome mutant cim3-1. Autophagy ratios were monitored in 
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cim3-1 cells growing at both permissive temperature (25°C) and at a sub-lethal inducing 
temperature (37°C). A preliminary spotting assay showed that α-synuclein cytotoxicity 
observed at 30°C (Figure 7) was reproducible at 25°C and was not disturbed by co-
expression of GFP-Atg8 (Figure 31A).  
 
   A 
 
 
 
 
 
 
B                                                                               C 
 
 
Figure 31. α-synuclein interference with autophagy in the cim3-1 mutant. (A) Spotting analysis 
of temperature-sensitive cim3-1 yeast. Cells were co-transformed with high-copy plasmids carrying 
untagged WT α-synuclein or versions under the control of GAL1 promoter and GFP-Atg8 under the 
control of copper-inducible promoter CUP1. Cells which expressed GFP-Atg8 but not α-synuclein 
served as control. (B, C) Quantification of autophagy in cim3-1 cells growing at (B) repressive 
temperature (25°C) and (C) at inducing temperature (37°C). Before α-synuclein induction, cells 
were incubated for 2h in raffinose medium supplemented with 50 µM CuSO4 to express GFP-Atg8 
then washed. (D, E). Quantification of autophagy during nitrogen starvation. Cells were induced for 
4h in SC medium with galactose then shifted to SD(-N) medium with galactose. Prior to α-synuclein 
induction, cells were incubated for 2h in raffinose medium supplemented with 50 µM CuSO4 to 
express GFP-Atg8 then washed. Probes were taken at 2 and 4h after the shift. Cells were grown 
(D) at repressive temperature (25°C) and (E) at induction temperature (37°C).  
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Autophagy assays in the cim3-1 background allowed for a comparison of autophagy 
processing during α-synuclein induction between wild type and proteasome-deficient cells. 
Autophagy ratios influenced by α-synuclein were generally comparable for wild type cells 
and for cim3-1 cells at non-inducing temperature during galactose induction (Figures 29A 
and 31B), with minor differences for A30P and TP α-synuclein. Autophagy rations were 
also comparable during nitrogen starvation (Figures 30A and 31D). The cim3-1 mutation 
was induced at 37°C. At this temperature, the autophagy ratios of mutant cells growing in 
galactose (Figure 31C) were again comparable to those of the parent strain (Figure 29A), 
except that at 8h of induction, the inhibitory effect of A53T α-synuclein was milder in the 
mutant than in wild type cells. However, under nitrogen starvation conditions, in contrast 
to the parent strain (Figure 30A), autophagy ratios of cim3-1 cells expressing α-synuclein 
were at all time points higher than those of α-synuclein-free cells (Figure 31E). This 
suggested that α-synuclein enhanced the induction of autophagy in the cim3-1 mutant. 
Interestingly, TP α-synuclein was also able to enhance autophagy induction, although this 
version was not cytotoxic in the spotting assays (Figure 31A) and did not affect autophagy 
ratios in wild type cells (Figure 30A).  
Taken together, these data suggested that under conditions of proteasomal inhibition α-
synuclein can enhance autophagy up-regulation.                                           . 
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4. DISCUSSION 
 
The main culprit of Parkinson’s disease is α-synuclein, a small protein which misfolds and 
accumulates, leading to neurodegeneration (Spillantini et al., 1998b). The pathogenicity of 
the disease has not been fully elucidated, yet many attempts are being made towards 
understanding the mechanisms of α-synuclein toxicity. α-synuclein has been studied in 
cell culture as well as in diverse model organisms including Drosophila melanogaster, 
Caenorhabditis elegans, Mus musculus and Saccharomyces cerevisiae. Although the 
yeast S. cerevisiae is a unicellular organism, its popularity among neurodegeneration 
model systems has increased considerably over the past decade. Since the first 
characterization of the yeast PD model by Outeiro and Lindquist in 2003, yeast has been 
used not only for understanding the behavior of α-synuclein in PD but also for identifying 
novel therapeutic strategies.   
 
 
4.1 Toxicity and localization of α-synuclein in yeast 
A central question addressed in the present study concerns the long-debated aspect of α-
synuclein toxicity in the yeast S. cerevisiae. It is important to note though, that the 
commonly used term toxicity is a rather general one. While α-synuclein toxicity in itself 
may elicit numerous and perhaps cumulative effects such as interference with the cell 
cycle, failure of quality control mechanisms, impairment of cellular degradation and 
oxidative stress, most reports often define α-synuclein toxicity in yeast solely by its ability 
 
“The important thing in science is not so much to obtain new facts 
as to discover new ways of thinking about them.” 
  
William Lawrence Bragg 
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to impair growth. For consistency reasons, this study also referes to the ability of α-
synuclein to inhibit yeast growth as toxicity or cytotoxicity.  
α-synuclein toxicity and aggregation are the first and foremost requirements for modelling 
Parkinson’s disease in yeast, corresponding to loss of dopaminergic neurons and 
respectively to Lewy body formation in PD brains. The first goal of this work was to 
determine under which conditions α-synuclein pathobiology can be studied in yeast. The 
challenge consisted in preserving α-synuclein’s natural properties in fluorescently tagged 
versions of the protein, which are indispensable for microscopic studies. Since reliable 
fluorescently tagged α-synuclein constructs are needed to investigate aggregate dynamics 
in living cells and since the literature did not offer a model for such constructs, it was 
important to obtain a comprehensive insight into the requirements for functional α-
synuclein-GFP fusions. For this purpose, a variety of constructs were analyzed, including 
high-copy/low-copy expression systems, GFP fusions to the N- and C- termini of α-
synuclein, different fluorescent tags and different linkers separating α-synuclein and the 
tag.  
Growth analysis revealed that tagged α-synucleins paralleled their untagged counterparts 
when the fluorescent tag was C-terminally fused to α-synuclein via a linker (Figures 7 and 
9). Overexpressed WT and A53T α-synuclein were toxic to growth and aggregated, as 
reported by previous studies (Dixon et al., 2005; Outeiro and Lindquist, 2003). The A30P 
variant caused only a moderate growth reduction and formed aggregates transiently, while 
the designer mutant TP α-synuclein had no effect on yeast growth and did not develop 
aggregates. These findings suggested a link between α-synuclein cytotoxicity and 
aggregation.  
While WT, A30P and A53T α-synuclein had previously been investigated in yeast, the 
phenotypic analysis of TP α-synuclein was performed here for the first time in this model 
organism (Figures 7, 9 and 10). The fact that TP did not aggregate in yeast (Figure 10) 
corresponds to previous in vitro results (Karpinar et al., 2009). However, in yeast TP was 
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not toxic to cell growth (Figure 7) as it was in models of worms, flies and mammalian 
neurons (Karpinar et al., 2009).    
The relevance of tag position and of linker in α-synuclein fusion constructs was 
emphasized when cells expressing α-synuclein variants N-terminally coupled to GFP via 
linker and C-terminally fused to GFP without linker grew uninhibited (Figure 12). The non-
toxic phenotype of these constructs correlated with their inability to aggregate. Several 
linkers tested (KLID, AAAG, SAAAG) showed that linker composition does not affect α-
synuclein toxicity or aggregation, therefore, the presence and not the nature of a linker is 
important for α-synuclein-GFP fussions (Figure 11). Moreover, the nature of fluorescent 
tag does not interfere with α-synuclein cytotoxicity and differences among tags rely only 
on aggregate morphology. For example, tags like GFP or mCherry give rise to well-
defined aggregates, whereas tags like myeGFP produce diffuse and unclear foci (Figure 
11).  
The importance of tag position can be attributed to structural and physiological differences 
between the α-synuclein termini. The N-terminus presumably needs to remain tag-free 
since the N-terminal region induces α-synuclein oligomerization and accumulation 
(Karube et al., 2008; Soper et al., 2008). Alternatively, the C-terminus is highly acidic and 
tends to inhibit aggregation (Cookson, 2005; Murray et al., 2003). Capping the C-terminus 
with a tag might therefore prevent this tendency.  
Live-cell fluorescence microscopy revealed a defined pattern for α-synuclein aggregation, 
which, as previously reported (Soper et al., 2008), starts with plasma membrane 
localization. This is likely due to the fact that α-synuclein is an amphyphatic protein which 
associates with lipid membranes (Davidson et al., 1998; Lucking and Brice, 2000; 
Narayanan and Scarlata, 2001). The association of α-synuclein with the yeast plasma 
membrane (Figures 10 and 13) correlates with its behavior in neuronal cells. There, the 
protein localizes at presynaptic terminals (Hsu et al., 1998) and it interacts with dopamine 
transporters located in the neuronal membrane to regulate the amount of dopamine 
entering the cell (Wersinger and Sidhu, 2003).  
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In the first two hours of α-synuclein-GFP induction, yeast cells exhibited fluorescence not 
only at the plasma membrane but also at the vacuolar membrane, as demonstrated by 
FM4-64 stainings (Figure 23). In addition, α-synuclein co-localized with endocytic vesicles 
and with fragmented vacuoles in a Δypt7 mutant, suggesting that the protein could be 
targeted to the vacuole, presumably for degradation. These data are consistent with 
recent findings that α-synuclein co-localizes with vesicular clusters involved in the 
secretory pathway (Soper et al., 2011). α-synuclein transport to the vacuole has been 
proven so far only for the A30P version (Flower et al., 2007). 
 
4.2 A30P α-synuclein can form aggregates in yeast 
Expression of untagged A30P α-synuclein as well as of A30P α-synuclein-KLID-GFP from 
a high-copy plasmid partially affected cell growth and resulted in aggregate formation 
(Figures 7, 9 and 10). Although A30P aggregated, the aggregation percentages of cells 
expressing this mutant were significantly lower than the aggregation percentages of cells 
expressing WT or A53T α-synuclein. Given that A30P aggregation was only transient, 
these data suggested that yeast can cope better with A30P aggregates.  
The gene dosage analysis revealed that, in contrast to WT and A53T α-synuclein, 
genomically-integrated A30P was not toxic and did not form aggregates (Figure 13). As 
the mutant was partially toxic and aggregated only when expressed from a 2µ plasmid, 
the prerequisite for the A30P α-synuclein phenotype is strong overexpression. 
The lack of A30P toxicity and aggregation upon low-copy expression as well as the 
moderate toxicity and transient aggregation achieved by overexpression may be due to an 
ability of yeast cells to degrade A30P faster than other versions. Consistently, autophagy 
monitoring assays revealed that in the first hours of induction A30P α-synuclein up-
regulates autophagy (Figure 29). The effect was no longer visible at later time points, 
meaning that autophagy induction is only transitory. Perhaps the transitory induction of 
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autophagy is sufficient to clear toxic A30P α-synuclein species, thus preventing their 
accumulation and relieving the cell from growth inhibition.  
Decreased binding of A30P α-synuclein to the plasma membrane, necessary for toxicity 
(Volles and Lansbury, 2007), might also explain the decreased toxicity of this mutant. 
A30P has long been reported not to associate with membranes as strongly as WT or 
A53T (Lashuel et al., 2002) due to a decreased affinity for lipid surfaces (Bussell and 
Eliezer, 2004).  
Besides not influencing yeast growth, A30P had also been reported not to aggregate in 
yeast (Dixon et al., 2005; Outeiro and Lindquist, 2003), which contradicted its behavior in 
mammalian cells and in vitro (Cookson, 2005; Giasson et al., 1999; Spillantini et al., 
1997). In this study the aggregation percentages of A30P were lower than those of WT 
and A53T α-synuclein and A30P aggregation was only transient, yet the ability of A30P α-
synuclein to form aggregates considerably extends the yeast PD model.  
 
4.3 α-synuclein aggregation is not a prerequisite for cytotoxicity  
Strains expressing α-synuclein from genomically-integrated copies offered a deeper 
insight into the relationship between growth toxicity and aggregation. Integration of one, 
two and three copies of α-synuclein alleles in the yeast genome aimed at determining the 
gene dosage required for the protein to be toxic and to aggregate. Three tandemic copies 
of WT and two of A53T α-synuclein were defined as thresholds for toxicity (Figure 13), 
which corresponds to the finding that α-synuclein allele multiplication such as duplication 
and triplication is linked to a familial form of PD (Hardy et al., 2006; Singleton et al., 2003). 
The fact that the threshold for A53T toxicity was lower than for WT correlates with a higher 
propensity of A53T to fibrilize, reported both in vitro and in transgenic mouse models 
(Conway et al., 1998; Giasson et al., 1999). Consistently, the number of Lewy bodies in 
PD dopaminergic neurons is higher for A53T than for WT α-synuclein (Sampathu et al., 
2003).  
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The gene dosage analysis revealed that α-synuclein was able to develop aggregates 
without impairing cell growth (Figure 13), which implies that a certain level of α-synuclein 
aggregation is needed for growth inhibition. While three copies of WT or two copies of 
A53T α-synuclein cause abundant aggregation and inhibit growth, one copy of WT or one 
copy of A53T results only in low aggregation which allows yeast to grow normally. In 
comparison, two copies of WT α-synuclein and overexpressed A30P α-synuclein develop 
moderate aggregation and do not inhibit growth (Figure 32). 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. α-synuclein gene dosage influences its aggregation and ability to impair yeast 
growth. WT α-synuclein expressed from one and two genomically-integrated tandemic copies, 
A53T α-synuclein expressed from one genomic copy and A30P α-synuclein expressed from a high-
copy vector result in low to moderate aggregation and do not impair yeast growth. Three WT and 
two A53T α-synuclein tandemic copies lead to abundant aggregation and impair growth. The 
GAL1-SNCA-GFP sequence is represented by squares and the α-synuclein variant is indicated in 
each square. The dotted lines on the left side represent genomic DNA.   
 
Another indication that a limited amount of aggregates may not be toxic for yeast was 
given by growth recovery experiments (Figure 15). Once the GAL1 promoter was shut off 
after 8h of α-synuclein expression, yeast cells recovered from α-synuclein-induced 
toxicity. Although cells could not immediately undergo cell division, later on, presumably 
after α-synuclein aggregates got cleared, they presented a normal colony formation kinetic 
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(Figure 16). Further promoter shut-off experiments proved that yeast cells can indeed 
clear α-synuclein aggregates as soon as the α-synuclein supply is interrupted. The 
observation that to a certain extent α-synuclein aggregates are not toxic is additionally 
supported by the fact that a number of PD neurons survive despite containing Lewy 
bodies (Forno et al., 1996). It remains unknown whether aggregates have a cytoprotective 
role, as they are assumed in late stages of the disease.   
Furthermore, evidence emerged that oligomeric species rather than aggregates of α-
synuclein are responsible for toxicity (Karpinar et al., 2009; Outeiro et al., 2008). In 
several PD models the rate of fibrilization and aggregation do not correlate with toxicity 
(Chen and Feany, 2005; Karpinar et al., 2009; Outeiro and Lindquist, 2003; Volles and 
Lansbury, 2002 and 2007). For example, the TP α-synuclein mutant is unable to 
aggregate, yet it causes neurotoxicity in several organisms (Karpinar et al., 2009). The 
fact that TP is not toxic to yeast growth (Figure 7) suggests that yeast might be more 
resistent to oligomeric states of α-synuclein than higher eukaryotes.  
 
4.4 Minor proteasomal contribution to α-synuclein aggregate 
clearance 
 
The present work questions the involvement of the ubiquitin-proteasomal system in α-
synuclein aggregate clearance in yeast. The fact that proteasome-impaired cells were 
able to clear α-synuclein aggregates upon promoter shut-off suggested an insignificant 
contribution of the 26S proteasome to aggregate clearance, which is consistent with 
earlier findings (Biasini et al., 2004). In particular, MG132 treatments did not enhance α-
synuclein accumulation to the extent that the protein could no longer be cleared (Figure 
19). Similarly, in neuroblastoma and oligodendroglial cells, inhibition of the proteasome by 
MG132 did not induce α-synuclein aggregation (Dyllick-Brenzinger et al., 2010; Riedel et 
al., 2010) and in yeast, A30P α-synuclein was still degraded despite proteasomal 
inhibition with the same drug (Flower et al., 2007). Supporting these findings, 
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polyubiquitination of α-synuclein has never been reported in yeast or in higher organisms 
(Stefanis et al., 2001).  
Mammalian PD models propose that most α-synuclein in the cell is degraded not by the 
proteasome but by lysosomal enzymes (Paxinou et al., 2001). A reason for diminished 
involvement of the proteasome in α-synuclein aggregate clearance could be that α-
synuclein itself alters the composition of the proteasome and impairs proteasomal 
degradation (Chen et al., 2005). While α-synuclein may be degraded by the proteasome 
(Bennett et al., 1999; Tofaris et al., 2001), an accumulation of the protein could inhibit the 
system (Lindersson et al., 2004). In turn, proteasomal inhibition would favor further α-
synuclein aggregation (Bedford et al., 2008; McNaught and Jenner, 2001).  
 
4.5 Involvement of vacuolar and autophagic pathways in α-
synuclein aggregate clearance 
 
The main degradation site in yeast is the vacuole. This is the final destination of many 
vesicles, including autophagosomes delivered via autophagy (Noda et al., 1995). The 
present study offers several lines of evidence that, in yeast, autophagy and the vacuole 
are major players in α-synuclein aggregate clearance. Treatments with the vacuolar 
protease inhibitor PMSF resulted in impaired α-synuclein aggregate clearance and 
increased α-synuclein aggregation (Figures 19 and 20), highlighting the importance of the 
vacuole in α-synuclein degradation. Supporting this finding, a Δpep4 mutant characterized 
by vacuolar defects presented decreased efficiency in clearing α-synuclein aggregates 
compared to the wild type cells (Figure 21). Both chemical and genetic approaches 
indicated the contribution of vacuolar pathways in α-synuclein aggregate clearance. Since 
aggregate clearance was not severely inhibited in Δpep4 cells, there could be more 
proteases involved in the process than the ones controlled by PEP4. For example, cell- 
culture models propose that α-synuclein can be degraded by the serine protease 
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neurosin, which is released from the mitochondria into the cytosol upon cellular stress 
(Iwata et al., 2003). 
A Δatg1 mutant defective in autophagy was unable to clear α-synuclein aggregates in the 
first 2h after promoter shut-off (Figure 21B), validating cell culture findings that autophagy 
inhibition slows down aggregate clearance (Fortun et al., 2003). The fact that Δatg1 could 
still clear aggregates, although with reduced efficiency, suggests that autophagy is 
involved in the process but not essential.  
Presumably, while bulky α-synuclein aggregates are preferentially degraded by 
autophagy, the extent to which they are degraded by the 26S proteasome is rather small. 
A higher contribution of autophagy than of the proteasome to α-synuclein degradation 
might also reflect the situation in mammalian systems, where autophagy inhibition 
promotes the accumulation of monoubiquitinated forms of α-synuclein (Rott et al., 2008; 
Yu et al., 2009). Cell culture models provide additional evidence that macroautophagy and 
chaperone-mediated autophagy but not the proteasome are involved in α-synuclein 
degradation (Vogiatzi et al., 2008).  
The fact that a cim3-1Δatg1 yeast double mutant impaired in both proteasomal and 
autophagic degradation was still able to clear α-synuclein aggregates (Figure 21) 
suggests additional yet unexplored mechanisms for aggregate clearance. In neuronal 
cells, one additional route for α-synuclein degradation is the endosomal-lysosomal 
pathway (Tofaris et al., 2011). 
 
4.6 Rapamycin-induced aggregate clearance 
An additional proof confirming the importance of autophagy in α-synuclein degradation 
came from experiments involving autophagy upregulation with the drug rapamycin. 
Rapamycin was reported to protect against huntingtin-induced neurodegeneration in flies 
and mice (Berger et al., 2006; Ravikumar et al., 2002) and to reduce α-synuclein 
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aggregation levels in cell culture (Webb et al., 2003) and in yeast (Zabrocki et al., 2005) 
models of PD.  
This work analyzed the conditions in which rapamycin influences α-synuclein aggregate 
clearance in yeast. Three different scenarios of rapamycin treatment were investigated, 
before, at the same time and after α-synuclein induction. The data argued in favor of 
rapamycin pre-treatment, i.e. before α-synuclein induction, for optimal effects. The 
analysis also showed that rapamycin-induced clearance is a function of α-synuclein 
concentration, as the drug affected high-copy expressed α-synuclein less than it affected 
low levels of the protein (Figure 26). Additionally, rapamycin-induced clearance does not 
discriminate among α-synuclein variants, which could suggest that α-synuclein aggregate 
clearance in yeast is a universal phenomenon (Figure 27).  
Although rapamycin treatment resulted in a reduction of aggregates, autophagy might not 
be the only pathway responsible for this effect. While rapamycin was reported to induce 
autophagy by inhibiting the TOR signaling pathway (Klionsky and Emr, 2000), TOR 
controls several other cellular processes, including ribosome biogenesis, transcription and 
translation (De Virgilio and Loewith, 2006; Sarbassov et al., 2005; Wullschleger et al., 
2006). Rapamycin-induced α-synuclein aggregate clearance could also occur through 
inhibition of protein synthesis which would reduce the monomeric concentration of α-
synuclein. Less monomeric α-synuclein would result in less oligomerization and 
consequently, in less aggregates.  
 
4.7 α-synuclein perturbs autophagy 
Autophagy must be essential in neuronal tissue since its impairment promotes 
neurodegeneration (Hara et al., 2006; Komatsu et al., 2006; Kuma et al., 2004). It is not 
exclusive though, that α-synuclein accumulation itself might impair autophagy. To 
investigate this possibility in yeast, this study employed macroautophagy-monitoring 
assays (Cheong et al., 2005). The transitory up-regulation of autophagy by A30P α-
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synuclein in the first two hours of induction (Figure 29A) can be linked to the low A30P 
aggregation levels and the mildly toxic yeast growth phenotype. Autophagy up-regulation 
could be part of a detoxification mechanism. The enhanced autophagic degradation would 
remove the toxic α-synuclein which can be harmful to the cell and trigger apoptosis 
(Bandyopadhyay and Cuervo, 2007; Stefanis et al., 2001). Apart from A30P, autophagy 
rates of cells expressing α-synucleins were comparable to those of control, suggesting 
that α-synuclein overexpression does not activate autophagy. However, eight hours of 
A53T α-synuclein induction inhibited autophagy and when autophagy was induced by 
means of nitrogen starvation, both WT and A53T α-synuclein delayed its activation (Figure 
30A). The more pronounced effect of A53T than of WT α-synuclein on autophagy 
inhibition correlates with the greater propensity of A53T to aggregate and with its lower 
toxicity threshold (Figure 13). 
The inhibitory/delaying effects on autophagy of WT and A53T α-synucleins correlated with 
their ability to impair yeast growth. Generally, inhibition of autophagy means inhibition of a 
major cellular degradation route otherwise used by the cell to clear proteins which are no 
longer needed, including the aggregated α-synuclein. Thus, autophagy inhibition would 
increase the concentration of α-synuclein and at the same time its probability to aggregate 
and burden the cell. This would be detrimental to cellular homeostasis, preventing the 
degradation not only of α-synuclein but of other dysfunctional proteins or organelles and 
would further trigger apoptotic signals, as already observed in many PD models 
(Ravikumar and Rubinsztein, 2006; Stefanis et al., 2001). Correspondingly, in yeast, the 
end effect would be growth inhibition, as observed in spotting assays (Figure 7).  
Autophagy-monitoring experiments in W303 yeast revealed that α-synuclein has an 
inhibitory effect on autophagy. Previous studies reported that α-synuclein inhibits 
autophagic pathways in neuronal cells and mice (Winslow et al., 2010; Xilouri et al., 
2009). This means that the mechanism of autophagy inhibition by α-synuclein is 
conserved from yeast to higher organisms. With its extensive genetic tools, yeast can thus 
be conveniently employed to study autophagy inhibition by α-synuclein in more detail.  
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Interestingly, under conditions of proteasomal impairment, the induction of autophagy 
through nitrogen starvation was enhanced by α-synuclein overexpression (Figure 31E). 
Although this effect was not detected under non-starvation conditions, it might suggest a 
link between proteasome inhibition and autophagy up-regulation by α-synuclein. If 
proteasomal inhibition in PD causes α-synuclein to enhance autophagy induction, the 
effect might correlate with the increased amount of autophagic structures in PD neurons 
(Anglade et al., 1997).  
Overall, this study had found that α-synuclein can inhibit autophagy and that autophagy 
and vacuolar pathways but not so much the proteasome are involved in α-synuclein 
aggregate clearance. It is possible that monomeric forms of α-synuclein are degraded by 
the proteasome while more complex oligomeric species are cleared by vacuolar pathways 
such as autophagy. Presumably, once accumulation and aggregation of α-synuclein 
impairs the proteasome (Chen et al., 2005), α-synuclein can no longer be degraded by 
this system and clearance of α-synuclein aggregated relies on the vacuole via autophagic 
pathways. Eventually, an increase in α-synuclein aggregation levels would also impair 
autophagy. As suggested by proter shut-off analysis (Figure 21), there may be additional 
pathways clearing α-synuclein aggregates (Figure 33).      
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Model of α-synuclein clearance. The 26 proteasome has a minor contribution to α-
synuclein aggregate clearance (interrupted arrow) while autophagy/vacuolar pathways clear α-
synuclein aggregates (straight arrow). Accumulation of α-synuclein affects and delays autophagy 
(dotted arrow). Inhibitory effects are indicated by the minus sign. Additional unexplored pathways 
can be invlolved in α-synuclein aggregate clearance.                                        . 
Autophagosome/
Vacuole 
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5. OUTLOOK AND FINAL REMARKS 
 
This study employed yeast to model pathological features of Parkinson’s disease with the 
aim of gaining a deeper insight into the cellular pathways responsible for α-synuclein 
degradation. Yeast offers unsurpassed advantages to study mechanisms of disease and 
the functionality of the yeast PD model is one of the proofs.  
To date, the toxic mechanisms of PD have not yet been fully elucidated and there is no 
effective treatment for the disease. The findings of this work can be used as a new 
starting point for developing therapeutic strategies for PD and related synucleopathies. 
Details like aggregation-prone constructs and gene dosage will have a major impact in 
designing future experiments, particularly genetic screens. Additionally, autophagy, shown 
to be involved in α-synuclein aggregate clearance and at the same time to be inhibited by 
α-synuclein accumulation, may serve as a target for therapeutic intervention. A curative 
solution could be either preventing autophagy inhibition or up-regulating the process. This 
could be extensively investigated in yeast by up-regulating the transcription of autophagy-
specific genes and by screening for chemicals that enhance the process.  
Taken together, the molecular biology, biochemistry and cell biology experiments in this 
study shed new light into the yeast model for Parkinson’s disease and have noteworthy 
implications for future research in the field. The results contribute to the understanding of 
α-synuclein toxicity mechanisms and can be further extended to higher model systems. 
Most importantly, yeast can be employed as a model for toxicity rescue and aggregate 
clearance, offering new inspiration in the quest for finding appropriate PD treatments.  
 
“We know very little, and yet it is astonishing that we know 
so much, and still more astonishing that so little knowledge 
can give us so much power.” 
 
   Bertrand Russell 
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